Document:

Exhibit 10.29

 

	
16 FEBRUARY 2012
    	
Strictly Private & Confidential
    

 

Business Acquisition Agreement

 

between

 

Amsterdam Molecular Therapeutics (AMT) Holding N.V.

as the Seller

 

uniQure B.V.

as the Purchaser

 

Forbion Co-Investment II Coöperatief U.A.

 

Coöperatieve AAC LS U.A.

 

And

 

FORBION Co-Investment COÖPERATIEF U.A.

 

as the Investor

 

Amsterdam Molecular Therapeutics (AMT) B.V.

 

and

 

Amsterdam Molecular Therapeutics (AMT)IP B.V.

as the Subsidiaries

 

relating to

 

the AMT human gene based therapy operations 

 

 

Simmons & Simmons LLP PO Box 79023 1070 NB Claude Debussylaan 247 1082 MC Amsterdam The Netherlands

T +31 20 722 2500 F +31 20 722 2599

 

 

CONTENTS

 

	
1.
    	
Interpretation
    	
6
    
	
 
    	
 
    	
 
    
	
2.
    	
Sale of the Business
    	
12
    
	
 
    	
 
    	
 
    
	
3.
    	
Funding of the Business
    	
12
    
	
 
    	
 
    	
 
    
	
4.
    	
Organisation of the Purchaser
    	
12
    
	
 
    	
 
    	
 
    
	
5.
    	
Extraordinary General Meeting and Recommendation
    	
13
    
	
 
    	
 
    	
 
    
	
6.
    	
Interim Period
    	
14
    
	
 
    	
 
    	
 
    
	
7.
    	
Alternative Offer and Alternative Funding
    	
15
    
	
 
    	
 
    	
 
    
	
8.
    	
Conditions Precedent
    	
16
    
	
 
    	
 
    	
 
    
	
9.
    	
Break fee
    	
17
    
	
 
    	
 
    	
 
    
	
10.
    	
Completion
    	
17
    
	
 
    	
 
    	
 
    
	
11.
    	
Co-operation following the Completion Date
    	
18
    
	
 
    	
 
    	
 
    
	
12.
    	
Post-Completion undertakings
    	
19
    
	
 
    	
 
    	
 
    
	
13.
    	
Dissolution, Distribution and delisting
    	
20
    
	
 
    	
 
    	
 
    
	
14.
    	
Seller Warranties
    	
21
    
	
 
    	
 
    	
 
    
	
15.
    	
Purchaser Warranties
    	
21
    
	
 
    	
 
    	
 
    
	
16.
    	
Additional Tax arrangements
    	
22
    
	
 
    	
 
    	
 
    
	
17.
    	
Confidentiality/Public Announcement
    	
25
    
	
 
    	
 
    	
 
    
	
18.
    	
Binding Effect/Assignment
    	
25
    
	
 
    	
 
    	
 
    
	
19.
    	
Partial Invalidity
    	
25
    
	
 
    	
 
    	
 
    
	
20.
    	
Entire Agreement; counterparts
    	
26
    
	
 
    	
 
    	
 
    
	
21.
    	
Expenses
    	
26
    
	
 
    	
 
    	
 
    
	
22.
    	
Dissolution and Annulment
    	
26
    
	
 
    	
 
    	
 
    
	
23.
    	
Notices
    	
26
    
	
 
    	
 
    	
 
    
	
24.
    	
Governing law and Jurisdiction
    	
27
    

 

1

 

SCHEDULES

 

	
schedule 1
    	
Confidentiality and Standstill Agreement
    
	
 
    	
 
    
	
schedule 2
    	
Fairness Opinion
    
	
 
    	
 
    
	
schedule 3
    	
IPR and Further Assets and Liabilities
    
	
 
    	
 
    
	
Schedule 4
    	
Purchaser Warranties
    
	
 
    	
 
    
	
Schedule 5
    	
Seller Warranties
    
	
 
    	
 
    
	
Schedule 6
    	
Project Kairos Term Sheet
    
	
 
    	
 
    
	
schedule 7
    	
Press Release
    
	
 
    	
 
    
	
Schedule 8
    	
Notices
    

 

2

 

THIS AGREEMENT is dated and made on 16 February 2012

 

BETWEEN:

 

(1)                                 Amsterdam Molecular Therapeutics (AMT) Holding N.V., a public company (naamloze vennootschap), incorporated under the laws of the Netherlands with its registered office (zetel) in Amsterdam, and its business address at Meibergdreef 61, 1105 BA, Amsterdam, the Netherlands and registered with the Commercial Register (Handelsregister) of Amsterdam under number 33301321 (the “Seller”);

 

(2)                                 uniQure B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid), incorporated under the laws of the Netherlands with its registered office in Amsterdam, and its business address at Gooimeer 2 35, 1411 DC Naarden, the Netherlands and registered with the Commercial Register of Gooi-, Eem- en Flevoland under number 54385229 (the “Purchaser”);

 

(3)                                 Amsterdam Molecular Therapeutics (AMT) B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid), incorporated under the laws of the Netherlands with its registered office (zetel) in Amsterdam, and its business address at Meibergdreef 61, 1105 BA, Amsterdam, the Netherlands and registered with the Commercial Register (Handelsregister) of Amsterdam under number 34275365 (“AMT BV”);

 

(4)                                 Amsterdam Molecular Therapeutics (AMT)IP B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid), incorporated under the laws of the Netherlands with its registered office (zetel) in Amsterdam, and its business address at Meibergdreef 61, 1105 BA, Amsterdam, the Netherlands and registered with the Commercial Register (Handelsregister) of Amsterdam under number 34275369 (“AMT IP BV”);

 

(5)                                 Forbion Co-Investment II Coöperatief U.A., a cooperative (coöperatie), incorporated under the laws of the Netherlands with its registered office in Naarden, and its business address at Gooimeer 2 35, 1411 DC Naarden, the Netherlands and registered with the Commercial Register of Gooi-, Eem- en Flevoland under number 53951956, represented by its managing director Forbion 1 CO II Management B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid), incorporated under the laws of the Netherlands with its registered office (zetel) in Naarden, and its business address at Gooimeer 2 35, 1411 DC Naarden, the Netherlands and registered with the Commercial Register of Gooi-, Eem- en Flevoland under number 53951956 (the “New Investor”);

 

(6)                                 Coöperatieve AAC LS U.A., a cooperative (coöperatie), incorporated under the laws of the Netherlands with its registered office in Amsterdam, and its business address at Gooimeer 2 35, 1411 DC Naarden, the Netherlands and registered with the Commercial Register of Gooi-, Eem- en Flevoland under number 34256402, represented by its managing director Forbion 1 Management B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid), incorporated under the laws of the Netherlands with its registered office (zetel) in Amsterdam, and its business address at Gooimeer 2 35, 1411 DC Naarden, the Netherlands and registered with the Commercial Register of Gooi-, Eem- en Flevoland under number 34249898 (the “Existing Investor I”);

 

3

 

(7)                                 FORBION Co-Investment COÖPERATIEF U.A., a cooperative (coöperatie), incorporated under the laws of the Netherlands with its registered office in Naarden, and its business address at Gooimeer 2 35, 1411 DC Naarden, the Netherlands and registered with the Commercial Register of Gooi-, Eem- en Flevoland under number 32142360, represented by its managing director Forbion 1 Management B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid), incorporated under the laws of the Netherlands with its registered office (zetel) in Amsterdam, and its business address at Gooimeer 2 35, 1411 DC Naarden, the Netherlands and registered with the Commercial Register of Gooi-, Eem- en Flevoland under number 342498 98 (the “Existing Investor II”);

 

each a “Party” and jointly referred to as the “Parties”. AMT BV and AMT IP BV jointly referred to as the “Subsidiaries” and the Seller and the Subsidiaries jointly referred to as the “Group”. The Existing Investor I and the Existing Investor II jointly referred to as the “Existing Investors”. The Existing Investors and the New Investor jointly referred to as the “Investor”.

 

BACKGROUND:

 

(A)                               The Group is engaged in the development of human gene based therapies. The Seller acts as the holding company for the Subsidiaries and is listed on NYSE Euronext in Amsterdam.

 

(B)                               Human gene-based therapies are intended to restore the natural function of the body as opposed to life long symptomatic treatment. These therapies are also very complex and it has taken years of innovative research to progress them to their current state where many of the traditional hurdles have been overcome. The Seller is a perceived leader in this field and the Executive Board (as defined hereafter) is of the view that the Group is well positioned to benefit from the anticipated growth of the area. It is against this background that the Seller had a regulatory setback with its lead product, which necessitated a change in strategy (pipeline focus).

 

(C)                               On 21 October 2011 the Seller was informed that the European Medicine Agency’s Committee for Medical Products for Human Use (CHMP) maintained its earlier opinion that the Group’s lead product is not approvable at this time. The CHMP argues that the Group has not shown clinical benefit in a sufficient number of patients for a sufficiently long time. The CHMP admits that it sees the technology platform risks as marginal.

 

(D)                               The fact that the CHMP issued a negative opinion regarding the Group’s lead product combined with the fact that the Group has very little cash available to continue the funding of its operations and the difficulties with attracting additional funding given the general economic climate and the Group’s prospects has led to concerns about the continuation of the Group’s business despite its strong position in the field.

 

(E)                                Because of the CHMP’s negative opinion, the Seller redefined its strategy and decided to focus its development efforts and financial resources on its Hemophilia B, GDNF and AIP programs whilst suspending all investment in its lead product and the DMD program and implemented a reorganisation, which reorganisation included the redundancy of around 50% of the Group’s employees and a reduction of the Group’s operations (the “Reorganisation”).

 

(F)                                 With the aim of further reducing the cost base and to generate funds by means of milestone payments and royalties, the Seller has engaged in partnering discussions with 

 

4

 

various pharma companies, especially regarding its Hemophilia B program. At the same time, it continuously explored all options with regard to the Business (as defined herein) and its financing. The outcome of this exploration is that the Seller was informed repeatedly by its bankers that they are unable to assist to attract additional financing in the current circumstances, that the Seller has not been able to attract any interest from a significant number of specialist biotech funds and investors that it approached directly, and that there are no viable possibilities of a strategic party making a bid for the Business currently available.

 

(G)                               Whilst the Seller anticipates that it may be possible to conclude a partnership on its Hemophilia B program in the first half of 2012, it is unlikely that it will be able to do so before its currently remaining cash is depleted. This means that to be able to continue its operations as a going concern, the Seller has an acute need to attract additional funding.

 

(H)                              The Existing Investors hold a substantial share interest in the Seller and are also the holders of the Loan Notes (as defined herein). In view of the difficult position of the Group, the Investor and the Seller have been discussing the possibilities of a transaction that allows for the continuation of the Group’s current activities and the further advancement of its pipeline and which takes into account the justified interests of the Group’s stakeholders, including the shareholders of the Seller.

 

(I)                                   On 22 December 2011 the Seller and the Existing Investors entered into a confidentiality and standstill agreement, a copy of which is attached hereto as schedule 1 (the “Confidentiality and Standstill Agreement”).

 

(J)                                   Because of conflict of interest considerations at the Executive Board and Supervisory Board level a special committee consisting of Supervisory Board members Messrs. Ferdinand Verdonck (Chairman), Philippe Van Holle, Joseph Feczko and François Meyer (the “Special Committee”) was established which has been allocated the AMT decision-making regarding the possible Transaction (as defined here below) with the Purchaser and the Investor.

 

(K)                              The Investor has been able to obtain funding commitments of €6.0 million in aggregate from a number of funds under its management, of which €5.0 million is committed by the New Investor that cannot invest in public companies, as a consequence of which taking the Business private is a prerequisite for this funding to be available.

 

(L)                                The Special Committee has established that the Investor’s €6.0 million funding commitment offers the only significant funding opportunity that is available to the Group and that without this funding the Seller will likely have to apply for a moratorium of payment or file for bankruptcy on short notice. As a consequence and in comparison to an insolvency scenario, the funding opportunity the Investor offers provides an opportunity for the continuation of the Business and a chance to retain shareholder value and preserve jobs.

 

(M)                            The Special Committee recognises that the Investor’s commitment to provide the aforementioned €6.0 million and to proceed with the Transaction is conditional to the Seller being able to obtain additional irrevocable financing commitments for the Business of at least €1.0 million in aggregate from an alternative investor, but believes that meeting this condition should be possible now that the Investor has expressed its willingness to further fund the Business.

 

5

 

(N)                               The discussions between the Parties have resulted in an agreement relating to the sale and purchase of the Business and its financing as further described in, and subject to the terms and conditions of this Agreement (the “Transaction”).

 

(O)                               Gene therapy is expected to advance medicine enormously in the area of many monogenic diseases and the Group has a leading position in this field. It is in this context that the Special Committee sees that the Transaction allows the Seller’s shareholders to maintain the value upside. It is the only financing transaction that the Special Committee believes to be able to execute on at the moment in the limited time frame available.

 

(P)                                 The Transaction requires the approval of the general meeting of shareholders of the Seller. On the basis that the Transaction is in the best interests of the Seller, its shareholders and the Business, the Special Committee supports the Transaction and shall recommend to the Extraordinary General Meeting (as defined hereafter) to approve the Transaction subject to the provisions of this Agreement.

 

(Q)                               The Seller and the Special Committee have received a fairness opinion (the “Fairness Opinion”) dated 17 February 2012 from Ernst & Young LLP in connection with the Transaction and supporting the Special Committee’s recommendation of the Transaction, stating that the Transaction is fair and reasonable and in the interests of the Seller ́s shareholders. A copy of the Fairness Opinion is attached as schedule 2.

 

(R)                               The Parties have complied with or will comply with the provisions of the SER Merger Code 2000 (SER-Fusiegedragsregels 2000) and the Works Council Act (Wet op de Ondernemingsraden).

 

AGREE AS FOLLOWS:

 

1.                                     Interpretation

 

1.1                               Unless explicitly stated otherwise, the following terms shall have the following meaning (and grammatical variations of such terms shall have corresponding meanings):

 

“Accounts Receivable” means all the accounts receivable of the Seller relating to the Business;

 

“Administration” means all the administration of the Group relating to the Business, whether in electronic or physical form, including but not limited to ownership titles of assets, bought and sold ledgers, purchase and sales day books and purchase and sales invoices, management information records and other accounting books and records of the Group including tax records relating to the Business;

 

“Advance Distribution” has the meaning ascribed thereto in clause 13.2;

 

“Agreement” means this business acquisition agreement including the recitals and the Schedules hereto;

 

“Alternative Funding” shall mean unconditionally (except for customary closing conditions) and fully committed funding that would result in the Business being funded until at least the end of the calendar year 2012, which in the reasonable opinion of the Special Committee, acting in good faith, offers a better proposition for the future and continuity of the Company and its stakeholders than the Transaction;

 

“Alternative Offer” has the meaning ascribed thereto in clause 7.1;

 

6

 

“Alternative Offer Announcement” has the meaning ascribed thereto in clause 7.2;

 

“Alternative Offer Period” has the meaning ascribed thereto in clause 7.2;

 

“AMT BV” means Amsterdam Molecular Therapeutics (AMT) B.V.;

 

“AMT BV Shares” means all of the issued and outstanding shares in the share capital of AMT BV;

 

“AMT BV Seller Loan” means the intra Group loan agreement between the Seller (as lender) and AMT BV (as borrower) and all (existing and future) rights and obligations thereunder;

 

“AMT IP BV” means Amsterdam Molecular Therapeutics (AMT)IP B.V.;

 

“AMT IP BV Seller Loan” means the intra Group loan agreement between the Seller (as lender) and AMT IP BV (as borrower) and all (existing and future) rights and obligations thereunder;

 

“AMT IP BV Shares” means all of the issued and outstanding shares in the share capital of AMT IP BV;

 

“Business” means all activities of the Group, its operations and all its assets and liabilities, and includes the Sale Shares, the Loan Notes, the Contracts and Convertible Loan Note Agreement, the Seller Loans, the Intellectual Property Rights and the Further Assets and Liabilities, but excludes the Excluded Contracts;

 

“Business Day” means any day of the week (excluding Saturdays and Sundays) on which banks are open for business in the Netherlands;

 

“CIT Fiscal Unity Termination Date” has the meaning ascribed thereto in clause 16.3(B);

 

“Completion” means the consummation of the Transaction as contemplated in clause 10;

 

“Completion Date” means the date on which Completion shall occur and which shall be determined in accordance with clause 10.1;

 

“Conditions Precedent” has the meaning ascribed thereto in clause 8.1;

 

“Confidentiality and Standstill Agreement” has the meaning ascribed thereto recital (I);

 

“Contracts” means all contracts entered into by the Group relating to the Business and all existing and future rights and obligations thereunder as further set out in schedule 3 but excluding the Excluded Contracts;

 

“Convertible Loan Note Agreement” means the agreement constituting the issuance of loan notes dated 22 December 2009 and made by the Seller and Coöperatieve AAC LS U.A. and Forbion Co-Investment Coöperatief U.A. and all existing and future rights and obligations of the Seller thereunder;

 

“DCC” means the Dutch Civil Code (Burgerlijk Wetboek);

 

“Deed of Assignment” has the meaning ascribed thereto in clause 6.2;

 

7

 

“Deed of Contribution” has the meaning ascribed thereto in clause 10;

 

“Distribution” has the meaning ascribed thereto in clause 13.2;

 

“Distribution Record Date” means the date that is the tenth Business Day following the date on which the dissolution of the Seller in accordance with clause 13.1 shall come into effect;

 

“Economic Ownership Transfer Agreement” means the agreement entered into on the date hereof by the Seller and the Subsidiaries pursuant to which the Seller agrees to transfer to the Subsidiaries the economic ownership of the NV-Business, subject to and on the terms and conditions set forth in such agreement;

 

“Employees” means all of the employees of the Group and includes the liabilities and obligations of the Seller towards or in relation to those employees, including all liabilities and obligations in relation to the Reorganisation;

 

“Encumbrance” means any right of pledge, mortgage, usufruct, retention of title or other security interest or other limited right (beperkt recht) whatsoever and any arrest, charge, attachment, option or lien or any similar concept that limits free and unrestricted title, under any applicable jurisdiction and any agreement or arrangement having the effect of providing security or priority;

 

“Excluded Contracts” means this Agreement, the listing agreement between the Seller and Euronext Amsterdam, the contract with the ENL agent and the payment agent, the liquidity provider agreement between the Seller and Kempen & Co N.V., the D&O Insurance policy of the Seller and any outstanding obligations under any stock option plan or other employee benefit plan of the Seller;

 

“Executive Board” means the executive board (raad van bestuur) of the Seller;

 

“Existing Investor I” means Coöperatieve AAC LS U.A., represented by its managing director Forbion 1 Management B.V.;

 

“Existing Investor II” means FORBION Co-Investment COÖPERATIEF U.A., represented by its managing director Forbion 1 Management B.V.;

 

“Existing Investors” means the Existing Investor I and the Existing Investor II;

 

“Extraordinary General Meeting” has the meaning ascribed thereto in clause 5.1;

 

“Fairness Opinion” has the meaning ascribed thereto in recital (Q);

 

“Final Distribution” has the meaning ascribed thereto in clause 13.2;

 

“Further Assets and Liabilities” means the Accounts Receivable, Administration, Intra-Group Trading Items, Employees and Contracts and any further assets and liabilities of the Group as further specified in schedule 3;

 

“Group” means the Seller and the Subsidiaries collectively;

 

“Guarantees” means any guarantees, indemnities, sureties, letters of comfort, joint and/or several liabilities or any other similar concept under applicable law pursuant to which a 

 

8

 

person or entity has or may become liable for the liabilities or obligations of another person or entity;

 

“Independent Tax Advisor” means an independent tax advisor or tax lawyer appointed by the Seller and Purchaser jointly with at least ten (10) years of experience as a practicing tax advisor or tax lawyer and being a member of the Dutch tax advisors association (Nederlandse Orde van Belastingadviseurs) or the Dutch association of tax lawyers (Nederlandse Vereniging van Advocaat-Belastingkundigen);

 

“Intellectual Property Rights” has the meaning ascribed thereto in schedule 3;

 

“Intra-Group Trading Items” means at any time, and from time to time, all amounts owed, outstanding or accrued in the ordinary course of trading between the Seller and the Subsidiaries in respect of intra group trading activity between them;

 

“Investor” means the New Investor and the Existing Investors;

 

“Loan Note 1” means the €700,000 5% convertible loan note due 2014 of the Seller dated 23 December 2009 and issued to and held by Coöperatieve AAC LS U.A. which is constituted by the Convertible Loan Note Agreement, and all the existing and future rights and obligations of the Seller thereunder;

 

“Loan Note 2” means the €4,300,000 5% convertible loan note due 2014 of the Seller dated 23 December 2009 and issued to and held by Forbion Co-Investment Coöperatief U.A. which is constituted by the Convertible Loan Note Agreement, and all the existing and future rights and obligations of the Seller thereunder;

 

“Loan Notes” means the Loan Note 1 and the Loan Note 2 collectively;

 

“Long Stop Date” means 12 May 2012;

 

“Matching Offer Right” has the meaning ascribed thereto in clause 7.2;

 

“New Investor” means Forbion Co-Investment II Coöperatief U.A., represented by its managing director Forbion 1 CO II Management B.V.;

 

“NV-Business” means all activities of the Seller, its operations and all its assets and liabilities, and includes the Accounts Receivable, the Contracts, the Intellectual Property Rights and the Further Assets and Liabilities (with the exception of the Administration), but excludes the Sale Shares, the Loan Notes, the Convertible Loan Note Agreement, the Seller Loans, the Excluded Contracts and the Economic Ownership Transfer Agreement;

 

“Opening Balance Sheet” means an opening balance sheet for Dutch corporate income tax purposes of AMT BV and AMT IP BV as at the CIT Fiscal Unity Termination Date as prescribed in article 13 of the Fiscal Unity Regulations 2003 (Besluit fiscale eenheid 2003) on a basis consistent with the Seller’s past practice (bestendige gedragslijn) and explanatory notes thereto;

 

“Party” or “Parties” means each of the Seller, the Purchaser, the Subsidiaries and the Investor individually or collectively;

 

“Purchaser” means uniQure B.V.;

 

9

 

“Purchaser Warranties” means the representations and warranties (garantieverklaringen) made by the Purchaser to the Seller contained in Schedule 4;

 

“Recommendation” means the Special Committee’s recommendation to the Extraordinary General Meeting to approve the Transaction;

 

“Reorganisation” has the meaning ascribed thereto in recital (E);

 

“Sale Shares” means the AMT IP BV Shares and the AMT BV Shares;

 

“Schedule” means a schedule to this Agreement;

 

“Secondary Tax Liability” means any secondary liability for Tax for which the Seller is liable on the basis of article 39 and 43 of the Dutch Collection Tax Act 1990 (Invorderingswet 1990);

 

“Seller” means Amsterdam Molecular Therapeutics (AMT) Holding N.V.;

 

“Seller Loans” means the AMT BV Seller Loan and the AMT IP BV Seller Loan collectively;

 

“Seller’s Tax Matters” has the meaning ascribed thereto in clause 16.3(A);

 

“Seller Warranties” means the representations and warranties (garantieverklaringen) made by the Seller to the Purchaser contained in Schedule 5;

 

“Shareholders Circular” has the meaning ascribed thereto in clause 5.1;

 

“Signing Date” means 16 February 2012, being the date on which this Agreement is made and dated;

 

“Special Committee” has the meaning ascribed thereto in recital (J) and consists of Supervisory Board members Messrs. Ferdinand Verdonck (Chairman), Philippe Van Holle, Joseph Feczko and François Meyer;

 

“Subsidiaries” means AMT BV and AMT IP BV;

 

“Supervisory Board” means the supervisory board (raad van commissarissen) of the Seller;

 

“Surviving Provisions” means clause 1 (Interpretation), clause 9 (Break fee), clause 17 (Confidentiality/Public Announcement), clause 18 (Binding effect/Assignment), clause 19 (Partial invalidity), clause 20 (Entire agreement), clause 21 (Expenses), clause 22 (Dissolution and Annulment) clause 23 (Notices) and clause 24 (Governing law and jurisdiction) which shall survive any termination of this Agreement;

 

“Tax” or “Taxes” means any and all taxes and governmental and local duties, levies and fees of every kind, including without limitation corporate income tax, value added tax, property tax, import and excise duties, EU charges, wage and personal income taxes, transfer tax, capital gains tax, inheritance tax, environmental tax, capital tax and customs duties, retributions, social security contributions and premiums, and any interest, increases or penalties thereon;

 

10

 

“Tax Authority” means any taxing or other authority competent to impose any liability in respect of Taxes or responsible for the administration and/or collection of Taxes or enforcement of any law in relation to Taxes;

 

“Tax Claim” means any notice, demand, assessment, letter or other document by or on behalf of any Tax Authority resulting in a liability of the Seller or the Subsidiaries in respect of Tax;

 

“Tax Liability” means any actual liability of the Seller in respect of Tax attributable to  the Business and the Subsidiaries or a Secondary Tax Liability;

 

“Tax Relief” includes any allowance, credit, deduction, exemption or set-off (including for the avoidance of doubt loss carry forwards) in respect of any Tax or relevant to the computation of any income, profits or gains for the purposes of any Tax, or any repayment of or saving of Tax (including any repayment supplement or interest in respect of Tax), and any reference to the use or set off of Tax Relief shall be construed accordingly and shall include use or set off in part and any reference to the loss or diminution of a Tax Relief shall include the absence, non-existence or cancellation of any such Tax Relief, or to such Tax Relief being available only in a reduced amount;

 

“Transaction” means the transaction contemplated by this Agreement and as further described in recital (N);

 

“Transaction Resolutions” has the meaning ascribed thereto in clause 5.4;

 

“Trust Foundation” has the meaning ascribed thereto in clause 4.1;

 

“uniQure DR(s)” has the meaning ascribed thereto in clause 2.2;

 

“VAT Fiscal Unity Termination Date” has the meaning ascribed thereto in clause 16.9; and

 

“Working Hours” means 9.30 a.m. to 5.30 p.m. on a Business Day.

 

1.2                               In this Agreement, a reference to:

 

(A)                               a “subsidiary” or “holding company” is to be construed in accordance with section 2:24(a) DCC;

 

(B)                               a “group company” or “affiliate” is to be construed in accordance with section 2:24(b) DCC;

 

(C)                               “material” or any similar expressions in this Agreement shall be construed in the context of the business of the Group taken as a whole;

 

(D)                               singular words shall include the plural and vice versa and words in a particular gender shall include all genders, unless the context requires otherwise;

 

(E)                                the word “include” or “including” are used to indicate that the matters listed are not a complete enumeration of all matters covered, unless the contrary is specifically stated;

 

(F)                                 the words “hereof”, “herein”, “hereto” and “hereunder” and words of similar import shall refer to this Agreement as a whole and not to any particular provision thereof;

 

11

 

(G)                               a person includes a reference to a body corporate, association or partnership; and

 

(H)                              a clause or a schedule is a reference to a clause or schedule of the actual agreement.

 

1.3                               In this Agreement, clause headings are inserted for convenience purposes only. They shall not affect the construction or interpretation of this Agreement.

 

1.4                               In case of conflict between or inconsistency of the provisions of the actual agreement and the contents of the Schedules, the provisions of the actual agreement shall prevail.

 

1.5                               The English language used in this Agreement intends to describe Dutch legal concepts only and the consequences of the use of this language in English law or any other law shall be disregarded. In case of conflict between Dutch legal concepts mentioned between brackets and/or in italics in this Agreement and the English translation thereof as used in this Agreement, the Dutch text, and its meaning thereof under Dutch law, will prevail.

 

2.                                     Sale of the Business

 

2.1                               Subject to the terms and conditions of this Agreement the Seller hereby agrees to contribute to the Purchaser and the Purchaser hereby agrees to accept from the Seller the Business.

 

2.2                               Subject to the conclusion of the Economic Ownership Transfer Agreement and the execution of the Deed of Assignment in accordance with clause 6.2, the Business shall be transferred in accordance with clause 10 by way of a contribution in kind (inbreng in natura) on depositary receipts for (class B) ordinary shares in the capital of the Purchaser (the “uniQure DRs”), which uniQure DRs shall be issued to the Seller as consideration. The number of uniQure DRs to be issued to the Seller shall be equal to the number of shares in the Seller that shall be outstanding on the Completion Date.

 

3.                                     Funding of the Business

 

3.1                               The Investor commits to provide equity funding of €6.0 million to the Purchaser.

 

3.2                               Pursuant to the Investor’s commitment to provide equity funding to the Purchaser, 9,771,986 (class A) ordinary shares in the capital of the Purchaser shall be issued to the Investor on or around the Completion Date at an issue price of €0.614 per share, being the mean closing share price of the Seller on NYSE Euronext in Amsterdam for the five Business Days prior to the Signing Date. In addition, the Seller’s debt under the Loan Notes as assumed by the Purchaser pursuant to the Transaction shall be converted in 5,320,000 (class A) ordinary shares in the capital of the Purchaser issued to the Existing Investors, using a conversion price of €1.00 per share.

 

4.                                     Organisation of the Purchaser

 

4.1                               The Investor shall procure that the Purchaser — a newly incorporated company without any liabilities — shall be structured and organized in accordance with the term sheet attached as Schedule 6 (Project Kairos Term Sheet) and that such structure and organisation shall have been implemented prior to Completion. This means inter alia that the Investor shall procure the incorporation of the trust foundation (the “Trust Foundation”) that shall issue the uniQure DRs and the preparation of the trust conditions pursuant whereto the Trust Foundation shall hold the (class B) ordinary shares in the capital of the Purchaser on trust and of the shareholders agreement to be entered into between the shareholders of the Purchaser.

 

12

 

4.2                               All documentation to be prepared by the Investor and its advisers pursuant to clause 4.1 shall be prepared in close consultation with the Seller’s advisers and require the Seller’s approval, acting reasonably.

 

5.                                     Extraordinary General Meeting and Recommendation

 

5.1                               The Transaction is subject to approval of the Seller’s general meeting of shareholders in accordance with section 2:107a DCC and the Seller’s articles of association. As soon as reasonably possible, the Seller shall convene an extraordinary general meeting of shareholders (the “Extraordinary General Meeting”) which shall be proposed to approve the Transaction and adopt the other Transaction Resolutions. The current target date of the Extraordinary General Meeting is 30 March 2012, which requires a convocation to be submitted no later than on 17 February 2012.

 

5.2                               On the basis that the Transaction as contemplated by this Agreement is in the best interests of the Seller and its stakeholders and the Business, the Special Committee supports the Transaction and shall give the Recommendation.

 

5.3                               The Recommendation may be modified or withdrawn by the Special Committee in the event an Alternative Offer having been made.

 

5.4                               In addition to the proposal to approve the Transaction, the Extraordinary General Meeting shall be proposed to resolve:

 

(A)                               subject to an Alternative Offer being made, to approve the disposal of the Business or a significant part thereof or the shares in capital of the Seller pursuant to an Alternative Offer, in view of section 2:107a of the DCC and section 20.1 of the Seller’s articles of association;

 

(B)                               subject to the execution of the Deed of Contribution, to dissolve and liquidate the Seller in accordance with section 47.1 of its articles of association with the members of the Executive Board becoming the liquidators of Seller’s dissolved property;

 

(C)                               subject to the execution of the Deed of Contribution, to approve the Advance Distribution;

 

(D)                               subject to the execution of the Deed of Contribution, to approve the Seller’s delisting from NYSE Euronext in Amsterdam;

 

(E)                                subject to the execution of the Deed of Contribution, to appoint AMT BV as the custodian (bewaarder) of the Seller’s books and records pursuant to section 2:24 of the Dutch Civil Code;

 

(F)                                 to discharge (decharge verlenen aan) (i) the members of the Supervisory Board and (ii) the members of the Executive Board;

 

(G)                               to confirm in view of a (potential) conflict of interest between the Seller and members of the Executive Board that the shareholders meeting shall not make an appointment as referred to in clause 19.3 of the Seller’s articles of association; and

 

13

 

(H)                              to approve an amendment of the Seller’s articles of association to increase its authorised share capital to €3,200,000, divided in 80,000,000 shares with a nominal value of €0.04 each.

 

(the proposal to approve the Transaction and each of the other proposals to the Extraordinary General Meeting referred to in clause 5.4(B) through 5.4(H) collectively the “Transaction Resolutions”). The Extraordinary General Meeting shall also serve to discuss the measures to be taken in view of the Seller’s equity position in accordance with section 2:108a DCC.

 

5.5                               The Existing Investors undertake with the Seller to support the Transaction and vote in favour of the Transaction Resolutions. The undertaking of the Existing Investors as per this clause 5.5 is unconditional and irrevocable and shall only terminate if this Agreement is terminated.

 

5.6                               In relation to the Extraordinary General Meeting the Seller shall make a shareholders circular (the “Shareholders Circular”) available to its shareholders. The Shareholders Circular, which shall be in English only, shall include the Recommendation and the Fairness Opinion. The contents of the Shareholders Circular shall be agreed between the Seller and the Purchaser prior to its release.

 

6.                                     Interim Period

 

6.1                               The Seller undertakes to the Purchaser that in the period from the Signing Date to the Completion Date, except with the approval of the Purchaser:

 

(A)                               none of the Subsidiaries’ articles of association or other constitutional documents will be changed or altered;

 

(B)                               each of the Subsidiaries shall use its best endeavours to carry on its respective business in all material respects in the ordinary and usual course and consistent with past practice;

 

(C)                               neither the Seller nor the Subsidiaries shall terminate or amend the employment agreements with any of the Employees other than with the prior written approval of the Purchaser;

 

(D)                               no Subsidiary shall allot, issue, redeem or repurchase securities, loan capital (including shareholder loans and profit participation rights) or shall become a party to any agreement to do so; and

 

(E)                                no dividend or other distribution or repayment of capital is, or shall be, paid or declared by the Seller or any of the Subsidiaries, other than the Distribution.

 

6.2                               The Seller further undertakes to the Purchaser that on the date hereof the Seller and the Subsidiaries will enter into the Economic Ownership Transfer Agreement. In connection therewith the Seller undertakes that in the period from the Signing Date to the Completion Date the legal title to the NV-Business shall be transferred by the Seller to the Subsidiaries by means of the execution of a deed of assignment (the “Deed of Assignment”) to be mutually agreed by the Seller and the Purchaser acting in good faith. In order to implement such transfer in accordance with the Deed of Assignment, the Seller shall undertake all necessary actions, including but not limited to:

 

14

 

(A)                               by informing the debtors of the Accounts Receivable in writing that the Accounts Receivable have been assigned to the Purchaser;

 

(B)                               by requesting the counterparties to the Contracts in writing for their co-operation to the transfer of contract to which the Seller is a party; and

 

(C)                               to the extent not already referred to in this section 6.2, the proper fulfilment of applicable transfer requirements in respect of the Intellectual Property Rights and Further Assets and Liabilities owned and/or held by the Seller.

 

6.3                               The Seller and the Purchaser hereby agree that in the period from the Signing Date to the Completion Date the Seller shall transfer the legal title to and economic ownership of the Seller Loans to the Subsidiaries, unless such transfer has materially adverse consequences for the Seller or the Subsidiaries; such determination to be made by the Seller and the Purchaser jointly acting reasonably.

 

7.                                     Alternative Offer and Alternative Funding

 

7.1                               For the purpose of this Agreement an “Alternative Offer” is an unconditional written bona fide offer by any third party for the Business or a significant part thereof or for the shares in the capital of the Seller, which may be a realistic and credible alternative to the Transaction for the Seller’s shareholders and other stakeholders.

 

7.2                               If in the period starting on Signing Date and ending on the 16th day prior to the date of the Extraordinary Meeting (such period the “Alternative Offer Period”) the Seller receives one or more Alternative Offer(s), the Seller will as soon as possible, after having notified the Purchaser of such Alternative Offer, publicly announce that the Alternative Offer was made and the terms and conditions thereof (the “Alternative Offer Announcement”). The Purchaser may in its sole discretion amend its offer for the Business in such a manner that it matches or is superior to the Alternative Offer (the “Matching Offer Right”) for a period of five days following the Alternative Offer Announcement.

 

7.3                               Before the Extraordinary General Meeting, the Special Committee shall indicate whether it intends, acting in good faith and taking into account the possible exercise of the Matching Offer Right by the Purchaser, to withdraw or materially modify its Recommendation.

 

7.4                               If one or more Alternative Offer(s) is/are made and announced by way of the Alternative Offer Announcement the Extraordinary General Meeting shall be proposed to vote both on the Transaction as well as on the Alternative Offer(s) in accordance with and as set out in clause 5.4(A). In such case, the resolution by the Extraordinary General Meeting in relation to the Transaction, or as the case may be, an Alternative Offer that is approved by the Extraordinary General Meeting shall be pursued by the Seller, and if more than one transaction is approved by the Extraordinary General Meeting the Seller shall pursue the transaction approved with the highest majority of the votes cast at the Extraordinary General Meeting.

 

7.5                               If the Seller pursues an Alternative Offer in accordance with clause 7.4, this Agreement may be terminated by each Party with immediate effect, by means of written notice to each other Party.

 

7.6                               If the Seller achieves attracting Alternative Funding prior to Completion and pursues with such Alternative Funding, each Party may terminate this Agreement with immediate effect by means of written notice to each other Party.

 

15

 

8.                                     Conditions Precedent

 

8.1                               The sale and purchase of the Business is subject to fulfilment on or before the Completion Date of each of the following conditions precedent (the “Condition(s) Precedent”):

 

(A)                               the adoption of the Transaction Resolutions by the Extraordinary General Meeting and, in case one or more Alternative Offer is/are made, the adoption of the resolution(s) under clause 5.4(A), provided in such case that the procedure as set out in clause 7.4 has been followed by the Seller;

 

(B)                               no application having been made to the Enterprise Division of the Amsterdam Court of Appeal pursuant to section 5:73 of the Act on financial supervision (Wet op het financieel toezicht) requesting that the Purchaser or any of its current shareholders make a public takeover bid;

 

(C)                               no breach of the Seller Warranties or default under any of the terms and provision of this Agreement on the part of the Seller having occurred which has not been remedied to the reasonable satisfaction of Purchaser and which breach or default could reasonably be expected to constitute a material adverse effect on the Business and is of such material nature that it cannot be reasonably expected that the Purchaser continues with the Transaction and no facts or circumstances having occurred which could lead to such breach or default;

 

(D)                               no breach of the Purchaser Warranties or default under any of the terms and provision of this Agreement on the part of the Purchaser having occurred which has not been remedied to the reasonable satisfaction of Seller and which breach or default is of such material nature that it cannot be reasonably expected that the Seller continues with the Transaction and no facts or circumstances having occurred which could lead to such breach or default;

 

(E)                                no action or proceeding by or before any court of law or arbitral tribunal or any governmental, provincial or municipal administrative body or authority or otherwise has been taken or instituted against any Party which may restrain, prohibit, invalidate or otherwise affect the transactions contemplated by this Agreement in any material respect;

 

(F)                                 Euroclear Nederland having accepted the uniQure DRs for inclusion in and settlement through its book entry systems;

 

(G)                               SenterNovem’s consent having been given to assign the agreement between the Seller and SenterNovem by the Seller to the Purchaser;

 

(H)                              irrevocable financing commitments being available to the Business in an amount of no less than EUR 1,000,000 (not including financing commitments extended by (funds managed by) the Investor); and

 

(I)                                   no material adverse change has occurred in the profitability, financial or trading position or the prospects of the Group.

 

8.2                               The Conditions Precedent under 8.1(A), 8.1(B), 8.1(E), 8.1(F) and 8.1(G) have been stipulated for the benefit of both the Seller and the Purchaser and may only be invoked or waived in writing by the Seller and the Purchaser acting jointly. The Conditions Precedent under, 8.1(C), 8.1(H) and 8.1(I) have been stipulated exclusively for the benefit of the Purchaser and may only be invoked or waived in writing by the Purchaser. The Condition 

 

16

 

Precedent under 8.1(D) has been stipulated exclusively for the benefit of the Seller and may only be invoked or waived in writing by the Seller.

 

8.3                               The Seller and the Purchaser will, after execution of this Agreement, co-operate with each other to complete the applicable procedures under the applicable competition laws and regulations in the most expeditious manner and will further use their reasonable efforts to cause the fulfilment of the Conditions Precedent.

 

8.4                               Should any Party become aware of anything which will or may prevent any of the Conditions Precedent from being satisfied it shall forthwith notify the same in writing to the other Parties.

 

8.5                               In the event that any Condition Precedent has not been fulfilled or, to the extent permitted by law and this Agreement, has been waived by the Purchaser or the Seller (as the case may be) by the Long Stop Date, the Party or Parties for the benefit of which the relevant Condition Precedent has been stipulated may terminate this Agreement with immediate effect, by means of written notice to each other Party.

 

8.6                               In the event this Agreement is terminated pursuant to clauses 7.5, 7.6 and 8.5, this Agreement shall cease to have effect, with the exception of the Surviving Provisions. In the event of such termination no Party shall be liable towards any other Party except for any liability towards any other Party in respect of a breach of this Agreement that took place prior to termination and except for the break fee that may be due pursuant to clause 9.

 

9.                                     Break fee

 

9.1                               A break fee is payable by the Seller to the Purchaser in the event this Agreement is terminated, except in the event of a termination of this Agreement as a result of the Condition Precedent under 8.1(D) being invoked, equal to compensate the Purchaser for all costs reasonably incurred (including, for the avoidance of doubt, legal fees) by the Purchaser and/or the Investor in connection with the Transaction, the break fee that may become payable pursuant to this clause 9.1 always being maximised at €200,000.

 

10.                              Completion

 

10.1                        Completion shall take place at the offices of Stibbe N.V. in Amsterdam as soon as possible after the date on which the last Condition Precedent under clause 8.1 is satisfied or, where permitted, waived in writing by the relevant Party or Parties, save as the Seller and the Purchaser may agree otherwise in writing, which is expected to occur on or about five April 2012.

 

10.2                        Following the conclusion of the Economic Ownership Transfer Agreement and the execution of the Deed of Assignment in the Interim Period in accordance with clause 6.2, the Business shall be transferred by the Seller to the Purchaser by means of the execution by one of the notaries of Stibbe N.V. of a notarial deed of contribution in kind (akte van inbreng) (the “Deed of Contribution”) to be mutually agreed by the Seller and the Purchaser acting in good faith, pursuant to which the (class B) ordinary shares in the capital of the Purchaser underlying the uniQure DRs shall be issued to the Trust Foundation, with the Trust Foundation immediately subsequent issuing the uniQure DRs to the Seller. By means of the execution of the Deed of Contribution — as a consequence of which the Business shall be transferred — the Seller shall transfer to the Purchaser and the Purchaser shall accept from the Seller on the Completion Date:

 

17

 

(A)                               the Loan Notes and the Convertible Loan Note Agreement at a value equal to the nominal value and accrued interest and transfer of contract — the Parties agree and acknowledge that any and all rights under the Loan Notes and the Convertible Loan Note Agreement to convert any amount due under any Loan Note into shares in the Seller are terminated and extinguished as of the moment and by means of the execution of the Deed of Contribution;

 

(B)                               the Administration (also by giving the Purchaser possession (bezitsverschaffing) thereto and, if necessary, notification to third parties holding (parts of) the Administration for the Group);

 

(C)                               the Seller Loans at a value equal to the nominal value and accrued interest, in the event the Seller has not transferred the legal title to and economic ownership of these Seller Loans to the Subsidiaries between the Signing Date and the Completion Date, due to the existence of materially adverse consequences for the Seller or the Subsidiaries; and

 

(D)                               the Sale Shares.

 

10.3                        To transfer the Business, on the Completion Date the Purchaser shall assume from the Seller and the Seller shall transfer to the Purchaser the Guarantees, whilst the Seller shall forthwith upon request of the Purchaser request the creditors of the Guarantees in writing for their consent to the transfer of the Guarantees to the Purchaser.

 

10.4                        To the extent any Employees are employed by Seller and not by the Subsidiaries and have not been transferred to the Purchaser on the Completion Date as a result of the transfer of the Sale Shares such Employees (and the rights and obligations under the employment agreements with such Employees in force at the Completion Date) will be transferred to the Purchaser by operation of law as a result of transfer of undertaking (overgang van onderneming) in accordance with section 7:663 et sec. DCC.

 

10.5                        The Purchaser shall procure the due compliance with section 2:204b DCC in relation to the contribution in kind by means of the Deed of Contribution, including the preparation of the description of the contribution and the preparation of the auditor’s statement.

 

11.                              Co-operation following the Completion Date

 

11.1                        The Parties shall do all such further acts and execute all such further documents as shall be necessary to fully effect the transfer of any part of the Business following Completion. The Parties shall take all necessary steps and cooperate fully to ensure that the Purchaser acquires (or assumes, as the case may be) the Business and the Parties shall at first request execute such documents in such form as may be agreed between the Seller and the Purchaser and take such other steps as are necessary or appropriate for vesting in the Purchaser all of the Seller’s rights and interests in the Business.

 

11.2                        Insofar as any of the Contracts or any other (asset or liability that is) part of the Business cannot be effectively transferred to the Purchaser without the consent of a third party or except by an agreement of novation on the Completion Date and the Parties have nevertheless proceeded with the Completion, then:

 

18

 

(A)                               the Purchaser acting on behalf of the Seller shall use all reasonable endeavours to obtain such consent or to procure a novation as soon as is reasonably possible following the Completion Date;

 

(B)                               unless and until such consent is obtained or novation has taken place the Purchaser shall for its own account perform on behalf of the Seller (but at the Purchaser’s expense) all the obligations of the Seller existing under such Contracts or (other asset or liability that is) part of the Business and the Seller will observe and comply with Purchaser’s reasonable instructions in relation to the same;

 

(C)                               any and all benefits under such Contracts or other (asset or liability that is) part of the Business shall be for the account of the Purchaser, and if received by the Seller, shall be forthwith paid on to the Purchaser by the Seller; and

 

(D)                               the Purchaser and the Seller may decide in mutual consent to terminate certain Contracts.

 

11.3                        The Purchaser shall procure, with effect from the Completion Date, the release of the Seller from any (joint and/or several) Guarantees and other liabilities given by, assumed by or binding upon the Seller in relation to any of the liabilities of the Group. The Purchaser shall indemnify and hold the Seller harmless and, against all amounts to be paid by it to any such (joint and several) Guarantees and other liabilities with respect to the Business (whether relating to the period before or after Completion).

 

12.                              Post-Completion undertakings

 

12.1                        The objective of the Transaction is that at Completion the entire Business and all its historic, actual and future assets and liabilities are transferred to the Purchaser, effectively transforming the Seller in a listed shell company with the uniQure DRs as its single asset and without any liabilities and that the uniQure DRs shall be subsequently available for distribution to the Seller’s shareholders by way of the Distribution as further set out in clause 13. In view of this objective:

 

(A)                               the Purchaser will, provided that Completion has taken place, indemnify the Seller and hold the Seller fully harmless (vrijwaren en schadeloosstellen) against all claims, liabilities, losses, costs (including the costs of legal and other advisers), damages, charges, expenses, proceedings and actions relating or attributable to the Business, whether relating to the period before or after Completion;

 

(B)                               the Purchaser shall compensate the Seller on a euro for euro basis for all costs associated to its operations as from Completion until the moment that the liquidation terminates and the Seller ceases to exist as further set out in clause 13, including but not limited to the costs and fees incurred and to be incurred pursuant to the Excluded Contracts, the listing, the preparation of the financial statements for the financial year 2011 and other financial reports, the 2012 annual general meeting and the Tax arrangements set out in clause 16;

 

(C)                               the Purchaser shall at no cost make the services and assistance of the Employees available to the Seller to the extent reasonably required or desired in relation to the Seller’s operations as from Completion until the moment that the liquidation terminates and the Seller ceases to exist, including but not limited to services and assistance in relation to prepare financial statements and other financial reporting, required disclosures, compliance matters and matters associated to the dissolution and liquidation of the Seller as further set out in clause 13.

 

19

 

12.2                        The Purchaser shall, and shall procure that the Subsidiaries shall, promptly and timely provide copies taken from the Administration and all further information and documentation relating to the Business that the Seller may reasonably require for the purpose of preparing its financial statements or otherwise request.

 

12.3                        Except to the extent that liability arises from the gross negligence (grove nalatigheid) or wilful misconduct (opzet) of the relevant person, the Purchaser (by way of irrevocable third party stipulation for no consideration) shall indemnify each member of the Special Committee, the Executive Board and the Supervisory Board and hold them fully harmless (vrijwaren en schadeloosstellen) against all claims, liabilities, losses, costs (including the costs of legal and other advisers), damages, charges, expenses, proceedings and actions relating or attributable to the Transaction, including for the avoidance of doubt the dissolution, the Distribution and delisting as set out in clause 13, and shall furthermore procure that appropriate D&O insurance for the benefit of the Special Committee and the members of the Executive Board and Supervisory Board shall be available and remain available at the Purchaser’s costs from Completion until the moment that the liquidation terminates and the Seller ceases to exist.

 

13.                              Dissolution, Distribution and delisting

 

13.1                        If and to the extent the Extraordinary General Meeting adopts the resolution to approve the Transaction and subject to the execution of the Deed of Contribution, the Seller shall be dissolved in accordance with section 47.1 of the Seller’s articles of association and section 2:23a et seq. DCC with the Executive Board members becoming the liquidators of the Seller’s dissolved property.

 

13.2                        Because the Seller’s dissolved property will consist of the uniQure DRs issued to the Seller in consideration for the Business without any known financial liabilities, and the financial condition is expected to justify the same, it is intended that the liquidators shortly after the Completion Date make an advance liquidation distribution to the Seller’s shareholders by distributing and allocating to each such shareholder one uniQure DR for each share in the Seller held on the Distribution Record Date (the “Advance Distribution”). Should any liquidation surplus remain after the Advance Distribution, the liquidators will make a final liquidation distribution to the Seller’s shareholders of such remaining liquidation surplus as soon as reasonably possible after the liquidation accounts and plan of distribution have become final (such final distribution, if any, the “Final Distribution”, the Advance Distribution and the Final Distribution (if any) also, the “Distribution”).

 

13.3                        The Distribution, to the extent it concerns the distribution of the uniQure DRs, shall be an allocation of such securities where there is no element of choice on the part of the recipient, including no right to repudiate the allocation. Consequently, the Distribution is no “offer of securities to the public” in the meaning of Chapter 5.1 of the Financial Supervision Act (Wet op het financieel toezicht) and article 2.1 (d) of the Prospectus Directive (2003/71/EC - 2010/73/EU). As a result the Distribution does not require the publication of a prospectus, nor does any other element of the Transaction.

 

13.4                        The Purchaser shall procure that upon issue the uniQure DRs shall be included in the Euroclear Nederland operated book entry systems, enabling the Distribution of the uniQure DRs being settled through such book entry system, resulting in one uniQure DR being credited in the securities account of each of the Seller’s shareholder for each share in the Seller held on the Distribution Record Date.

 

20

 

13.5                        When the liquidation ends the Seller shall cease to exist, which shall effectively also result in the Seller’s delisting, to the extent the delisting cannot be achieved at an earlier date in consultation with Euronext Amsterdam and subject to such conditions as Euronext Amsterdam may propose.

 

14.                              Seller Warranties

 

14.1                        Subject to Completion and the provisions of this clause 14, the Seller represents and warrants to the Purchaser that each of the Seller Warranties is accurate on the Signing Date and shall be accurate on the Completion Date.

 

14.2                        The Purchaser acknowledges that the Seller Warranties are the only representations, warranties or other assurances of any kind on which the Purchaser may rely in entering into this Agreement. No statement made or information provided by or on behalf of the Seller, the Subsidiaries or any of their affiliates or advisors can be regarded as a representation, warranty or other assurance of any kind.

 

14.3                        Subject to the limitations of clauses 14.4 through 14.6, in the event of a breach of any Seller Warranty, the Seller shall, at the direction of the Purchaser, pay to the Purchaser or any other designated person, at the option of the Purchaser, an amount equal to:

 

(A)                               the amount necessary to place the Purchaser and the Subsidiaries in the position in which each of them would have been if the relevant breach had not occurred; or

 

(B)                               the actual amount of damage (schade) suffered or incurred by the Purchaser.

 

14.4                        The aggregate liability of the Seller pursuant to this clause 14 shall not exceed €1,000,000.

 

14.5                        The Purchaser’s right to claim compensation for damage for a breach of one or more of the Seller Warranties lapses on the earlier of (i) six months after the Signing Date and (ii) the moment on which the Seller dissolves, unless prior to the relevant expiry date valid notice of a valid claim has been given by the Purchaser to the Seller in accordance with clause 14.6.

 

14.6                       If the Purchaser becomes aware of anything that constitutes or may constitute a breach of or may be inconsistent with the Seller Warranties, the Purchaser will give immediate written notice to the Seller of all the relevant facts known at the time to the Purchaser. The Purchaser shall have no right to claim damages if the Purchaser has not initiated legal proceedings against the Seller within two months after the lapse of the relevant limitation period referred to clause 14.3.

 

15.                              Purchaser Warranties

 

15.1                        The Purchaser represents and warrants to the Seller that each of the Purchaser Warranties is accurate on the Signing Date and shall be accurate on the Completion Date.

 

15.2                        The Purchaser shall be liable to the Seller for and shall indemnify and hold the Seller harmless against all losses and damages (including, without limitation, all reasonably incurred legal fees and costs of litigation) suffered by the Seller as a result of a breach of one or more of the Purchaser Warranties.

 

21

 

16.                              Additional Tax arrangements

 

Tax indemnities

 

16.1                        The Purchaser will indemnify the Seller and hold the Seller fully harmless against all actions, claims, costs, interest and expenses (including fees of legal and other advisers), provided that these costs and expenses have been reasonably incurred, in relation to:

 

(A)                               any actual liability in respect of Tax for which the Seller is liable as a result of any event occurring before or on Completion Date or in respect of any profits earned or revenues realised before or on the Completion Date (excluding for the avoidance of doubt any Dutch dividend withholding tax), which are attributable to the Business and/or the Subsidiaries;

 

(B)                               any Secondary Tax Liability.

 

Due date for payment

 

16.2                        A payment to be made by the Purchaser under clause 16.1(A) or 16.1(B), shall be made within ten Business Days after the earlier of (i) the date on which the Seller and the Purchaser have agreed jointly (x) not to file an appeal against a Tax assessment or similar instrument which constitutes a payment obligation, or (y) not to file a further appeal against a decision with respect to a Tax Liability; (ii) the date on which a final decision is made on appeal with respect to a Tax Liability against which no further appeal is possible or (iii) the date on which the Seller, with the prior consent of the Purchaser, in the context of a Tax Liability has made a payment to any Tax Authority on the basis of a Tax assessment or similar instrument which constitutes a payment obligation which cannot be suspended or is paid to avoid interest or penalties.

 

Procedural arrangements

 

Seller’s Tax Matters

 

16.3                        The Parties agree that:

 

(A)                               the Seller or such professional advisers as the Seller may determine shall, with due observance of clause 16.3(E) and 16.3(F), conduct the preparation, submission and negotiation of all returns and computations, the preparation and submission of all correspondence relating to such returns and computations and the agreement of all matters relevant to the Tax position of the CIT Fiscal Unity, the Seller and, for any period ending on or before the Completion Date, the Subsidiaries (the “Seller’s Tax Matters”);

 

(B)                               the Seller and Purchaser will agree jointly on the date of termination of the Dutch fiscal unity for Dutch corporate income tax purposes within the meaning of article 15 Dutch Corporate Income Tax Act 1969 (Wet op de vennootschapsbelasting 1969) (the “CIT Fiscal Unity Termination Date”) and shall not shall take any positions in their Tax affairs inconsistent therewith. Within three months following the Completion Date, the Seller shall present the Purchaser with an Opening Balance Sheet The Purchaser is entitled to dispute the Opening Balance Sheet in writing within 10 Business Days after delivery thereof. In case the Seller and the Purchaser are not able to remove the objections of the Purchaser amicably within 5 Business Days, an Independent Tax Advisor shall decide on the objection and to the extent necessary revise the Opening Balance Sheet.

 

22

 

(C)                               Any Tax Relief attributable to the Business and/or the Subsidiaries shall be transferred by the Seller to the Purchaser or the Subsidiaries to the maximum extent possible, such that it will be available to the Purchaser or the Subsidiaries after Completion. In accordance with article 15af of the Dutch Corporate Income Tax Act, the Seller and the Subsidiaries shall, together with the CIT Tax return for the period during which the Fiscal Unity Termination Date occurs, submit a request to the Tax authorities to transfer to the Subsidiaries the remaining losses available for loss carry forward attributable to the Subsidiaries.

 

(D)                               the Purchaser shall, and shall procure that the Subsidiaries shall co-operate fully with the Seller for the purpose of the Seller’s Tax Matters and the compilation of the Opening Balance Sheet and will cause the Subsidiaries to provide the Seller promptly and timely with any information received by the Purchaser or the Subsidiaries, which is relevant to the Seller’s Tax Matters and with any information as deemed necessary by the Seller to compile the Opening Balance Sheet and upon the Seller’s first request with all reasonable information, documentation and assistance requested with reasonable priority and will provide Seller and its advisers access to the Subsidiaries’ books and records during reasonable business hours, to the extent reasonably required to assess the Tax position of the Seller;

 

(E)                                the Seller shall keep the Purchaser fully informed of the progress of all matters relating to the Seller’s Tax Matters and shall provide the Purchaser with copies of all written correspondence with any Tax Authority if and to the extent relevant for the Tax affairs of the Seller;

 

(F)                                 the Seller shall not, without the written consent of the Purchaser, file returns, make claims, elections or statements or enter into an agreement or settlement with any Tax Authority in respect of the Seller’s Tax Matters if such a return, claim, election, statement or such an agreement or settlement could reasonably lead to adverse Tax consequences for the Purchaser.

 

(G)                               the Subsidiaries shall, subject to clause 16.3(E) and 16.3(F) being fulfilled, immediately authorise, sign and submit to the relevant Tax Authority such returns and other ancillary information, accounts, statements and reports relating to a relevant Tax period and make such claims and elections and give such consents to comply with all procedural requirements in respect of the making or giving of such returns, ancillary information, accounts, statements and reports or such claims, elections or consents as the Seller may direct in writing to the extent that they relate to the Seller’s Tax Matters;

 

(H)                              if the Seller directs the Subsidiaries to make a payment for Wage Taxes, social securities and VAT to any Tax Authority in respect of any matter over which the Seller has conduct, the Subsidiaries shall make the payment to the relevant Tax Authority within two Business Days of the Subsidiaries receiving the written instruction from the Seller;

 

(I)                                   The Purchaser nor the Subsidiaries shall take any positions in their Tax affairs inconsistent with the Opening Balance Sheet (as revised by the Independent Tax Advisor).

 

16.4                        The Seller shall up to the Completion Date continue its Tax affairs and the Tax affairs of the Subsidiaries in a manner consistent with past practice (bestendige gedragslijn), and:

 

23

 

(A)                               the Seller shall not deviate and shall cause the Subsidiaries not to deviate from the principles consistently applied and the courses of action consistently followed in respect of (i) the determination of the profit for Tax purposes (fiscale winstbepaling); and (ii) the valuation of the assets and liabilities for Tax purposes; and

 

(B)                               the Seller shall ensure that no decisions or any other actions are taken by it or the Subsidiaries which may prejudice or otherwise cause an adverse change in its Tax position or the Tax position of the Subsidiaries,

 

unless required by applicable Tax law or written permission has been granted by the Purchaser

 

The terms ‘consistently applied principles’ and ‘course of action consistently followed ‘ in the previous sentence, inter alia, relate to the depreciation schedule, transfer pricing, and the moment revenue, income, gain, loss, cost and expenditures are recognised for Tax and accounting purposes.

 

Purchaser’s Tax Matters

 

16.5                        With effect from Completion, the Purchaser and its advisers shall have sole conduct of all Tax affairs of the Subsidiaries other than the Seller’s Tax Matters.

 

Conduct of Tax Claims

 

16.6                        Subject to Completion, if the Seller receives any Tax Claim, the Seller shall give or procure that notice in writing is given to the Purchaser as soon as is reasonably practicable.

 

16.7                        The Purchaser shall be entitled at its own expense to resist the Tax Claim in the name of the Seller or as the case may be the Subsidiaries and to have the conduct of any appeal, dispute, compromise or defence of the Tax Claim and of any incidental negotiations and the Seller will give and procure the Subsidiaries to give the Purchaser all reasonable co-operation, access and assistance for the purposes of considering and resisting the Tax Claim.

 

16.8                        If the Purchaser does not elect to resist that Tax Claim in the name of the Seller, the Seller shall give the Purchaser drafts of all communications it intends to make in relation to the Tax Claim at least five Business Days before the communication is made, shall make such amendments as the Purchaser shall request unless, in the reasonable opinion of the Seller, such amendments may adversely affect the tax position of the Seller, before it makes such communication and shall promptly provide the Purchaser with copies of all correspondence relating to the Tax Claim.

 

VAT

 

16.9                        The Seller shall cause the request referred to in article 43, paragraph 1 of the Dutch Collection Tax Act 1990 (Invorderingswet 1990) to be submitted to the competent Tax Authorities on the Completion Date in order to effectuate the termination of the Dutch fiscal unity for Dutch VAT purposes within the meaning of article 7 paragraph 4 Dutch VAT Act 1968 (Wet op de omzetbelasting 1968) between the Seller and the Subsidiaries as from the Completion Date (the “VAT Fiscal Unity Termination Date”).

 

24

 

16.10                 The Seller and the Purchaser shall determine jointly whether there are registrations for VAT purposes of the Seller’s Group outside The Netherlands that have to be terminated and shall cause the termination of such registration(s). The Purchaser shall in its sole discretion determine whether to apply for new registrations for VAT purposes of the Purchaser’s Group, as from the Completion Date.

 

Confidentiality

 

16.11                 Any information obtained by a Party from another Party in connection with any Tax matters to which this clause 16 applies shall be kept confidential, except as otherwise provided in this Agreement and except as may be otherwise necessary in connection with the filing of tax returns or claims for refund or in conducting an audit or other tax proceedings relating to the disclosing party or to comply with any statutory requirements.

 

Miscellaneous

 

16.12                 The provisions of this clause 16 exhaustively constitute the obligations of the Seller relating to Tax.

 

17.                              Confidentiality/Public Announcement

 

17.1                        Except to the extent required by law (including the SER Merger Code 2000) or applicable stock exchange regulations and in case of such requirement only after prior consultation with the other Party (to the extent reasonably practicable), the Parties will not disclose the content of this Agreement and the discussions and negotiations to any third party.

 

17.2                        The Parties will consult and agree in advance with each other on the timing and tenor of any public announcement with respect to the Transaction, provided however that no Party shall be required to abstain from any public announcement that that is required by law or applicable stock exchange regulations.

 

17.3                        Nothing in this clause 17 shall affect the rights and obligations of the relevant Parties under the Confidentiality and Standstill Agreement.

 

17.4                        Immediately after the execution of this Agreement, the Seller shall issue the press release in the agreed form attached as schedule 7.

 

18.                              Binding Effect/Assignment

 

18.1                        All the terms, provisions, warranties, covenants and conditions of this Agreement shall only be binding upon and inure to the benefit of and be enforceable by the Parties after this Agreement has been signed by the Parties.

 

18.2                        Except as expressly provided otherwise, this Agreement does not contain any third-party stipulation (derdenbeding).

 

18.3                        This Agreement and any rights and obligations of the Parties hereto may not be transferred, assigned or delegated by any Party to a third party without the prior written consent of the Seller.

 

25

 

19.                              Partial Invalidity

 

19.1                        In the event that one or more clauses of this Agreement or of the Schedules are established to be non-binding, the other clauses of this Agreement and of the Schedules will continue to be effective. The Parties are obliged to replace the non-binding clauses with other clauses that are binding, in such a way that the new clauses differ as little as possible from the non-binding clauses, taking into account the object and the purpose of this Agreement.

 

20.                              Entire Agreement; counterparts

 

20.1                        This Agreement including the Schedules thereto contains all arrangements, which the Parties have made on the subject. They shall replace and supersede all other (previous) arrangements and agreements, which the Parties have made or have entered into on the subject. This Agreement can only be altered or modified by means of a document signed by the Parties.

 

20.2                        This Agreement may be executed in any number of counterparts by the Parties to it, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

21.                              Expenses

 

21.1                        Each of the Parties hereto shall pay its own expenses incurred or to be incurred in connection with the negotiation and preparation of this Agreement and the transactions contemplated thereby, except for the expenses incurred or to be incurred by the Investor, which expenses shall be borne by the Purchaser.

 

22.                              Dissolution and Annulment

 

22.1                        Each of the Parties hereby waives the right, and each of the Parties accepts the same, to cancel (opzeggen), to dissolve or bring an action to dissolve this Agreement (ontbinding) and/or to annul or bring an action to annul this Agreement (vernietiging) or alter this Agreement on the basis of unforeseen circumstances (onvoorziene omstandigheden) or suspend (opschorten) any of the obligations assumed hereunder as from the moment of its execution.

 

22.2                        Each of the Parties hereby further waives, and each of the Parties accepts the same for the other Parties, the applicability of title 1 of Book 7 DCC.

 

23.                              Notices

 

23.1                        All announcements or notices to the Parties will be done in writing and delivered to the relevant Party at its address specified in Schedule 8 as long as a Party does not give notice to the other Parties of any other address.

 

23.2                        Subject to clause 23.3, in the absence of evidence of earlier receipt, any notice or other communication given under this Agreement shall be deemed to have been duly given as follows:

 

(A)                               if delivered personally or by courier, on delivery;

 

(B)                               if sent by registered mail, two clear Business Days after the date of posting; and

 

26

 

(C)                               if sent by email, at the time of completion of transmission provided that the recipient of the email acknowledges receipt of such email.

 

23.3                        Any notice given under this Agreement outside Working Hours in the place to which it is addressed shall be deemed not to have been given until the start of the next period of Working Hours in such place.

 

24.                              Governing law and Jurisdiction

 

24.1                        This Agreement and any contractual and non contractual obligations arising there from shall be governed exclusively by Dutch law.

 

24.2                        All disputes arising out of or in connection with this Agreement or further agreements resulting thereof shall be settled by arbitration in accordance with the rules of the Netherlands Arbitration Institute (Nederlands Arbitrage Instituut). The Arbitral Panel will consist of three arbitrators and the proceedings will be conducted in English (unless the Parties agree otherwise) in Amsterdam, The Netherlands. The Arbitral Panel will rule in accordance with provisions of Dutch law.

 

[signature pages follow ]

 

27

 

This Agreement is executed in three copies in Amsterdam on 16 February 2012 by:

 

	
Amsterdam   Molecular Therapeutics (AMT) Holding N.V.
    	
 
    	
Amsterdam   Molecular Therapeutics (AMT) Holding N.V.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/Jörn Aldag
    	
 
    	
/s/PJ Morgan
    
	
By: Mr. J. Aldag
    	
 
    	
By: Mr. P.J. Morgan
    
	
Title: Chief Executive   Officer
    	
 
    	
Title: Chief Financial   Officer
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
uniQure   B.V.
    	
 
    	
uniQure   B.V.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/H.A. Slootweg
    	
 
    	
/s/M.A. van Osch
    
	
By: Forbion 1 Co II   Management B.V.
    	
 
    	
By: Forbion 1 Co II   Management B.V.
    
	
Title: Director
    	
 
    	
Title: Director
    
	
By:
    	
H.A. Slootweg
    	
 
    	
By:
    	
M.A. van Osch
    
	
Title:
    	
Director
    	
 
    	
Title:
    	
Director
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Amsterdam   Molecular Therapeutics (AMT) B.V.
    	
 
    	
Amsterdam   Molecular Therapeutics (AMT) B.V.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Jörn Aldag
    	
 
    	
/s/PJ Morgan
    
	
By: Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
By: Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    
	
Title: Director
    	
 
    	
Title: Director
    
	
By: Mr. J. Aldag
    	
 
    	
By: Mr. P.J. Morgan
    
	
Title: Chief Executive   Officer
    	
 
    	
Title: Chief Financial   Officer
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Amsterdam   Molecular Therapeutics (AMT)IP B.V.
    	
 
    	
Amsterdam   Molecular Therapeutics (AMT)IP B.V.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Jörn Aldag
    	
 
    	
/s/PJ Morgan
    
	
By: Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
By: Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    
	
Title: Director
    	
 
    	
Title: Director
    
	
By: Mr. J. Aldag
    	
 
    	
By: Mr. P.J. Morgan
    
	
Title: Chief Executive   Officer
    	
 
    	
Title: Chief Financial   Officer
    

 

28

 

	
Forbion   Co-Investment II Coöperatief U.A.
    	
 
    	
Forbion   Co-Investment II Coöperatief U.A.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/H.A. Slootweg
    	
 
    	
/s/M.A. van Osch
    
	
By: Forbion 1 Co II   Management B.V.
    	
 
    	
By: Forbion 1 Co II   Management B.V.
    
	
Title: Director
    	
 
    	
Title: Director
    
	
By:
    	
H.A. Slootweg
    	
 
    	
By:
    	
M.A. van Osch
    
	
Title:
    	
Director
    	
 
    	
Title:
    	
director
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Coöperatieve   AAC LS U.A.
    	
 
    	
Coöperatieve   AAC LS U.A.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/H.A. Slootweg
    	
 
    	
/s/M.A. van Osch
    
	
By: Forbion 1 Management   B.V.
    	
 
    	
By: Forbion 1 Management   B.V.
    
	
Title: Director
    	
 
    	
Title: Director
    
	
By:
    	
H.A. Slootweg
    	
 
    	
By:
    	
M.A. van Osch
    
	
Title:
    	
Director
    	
 
    	
Title:
    	
director
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
FORBION Co-Investment COÖPERATIEF U.A.
    	
 
    	
FORBION Co-Investment COÖPERATIEF   U.A.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/H.A. Slootweg
    	
 
    	
/s/M.A. van Osch
    
	
By: Forbion 1 Management   B.V.
    	
 
    	
By: Forbion 1 Management   B.V.
    
	
Title: Director
    	
 
    	
Title: Director
    
	
By:
    	
H.A. Slootweg
    	
 
    	
By:
    	
M.A. van Osch
    
	
Title:
    	
Director
    	
 
    	
Title:
    	
director
    

 

29

 

SCHEDULE 1 — CONFIDENTIALITY AND STANDSTILL AGREEMENT

 

30

 

22 December 2011

 

Confidentiality and Standstill Agreement

 

between

 

Amsterdam Molecular Therapeutics (AMT) Holding N.V.

 

and

 

Forbion I Management B.V.

 

relating to Project Kairos

 

Simmons & Simmons

 

Simmons & Simmons LLP PO Box 79023 1070 NB Claude Debussylaan 247 1082 MC Amsterdam The Netherlands

T +31 20 722 2500 F +31 20 722 2599

 

Simmons & Simmons LLP is a limited liability partnership registered with the Registrar of Companies for England & Wales with number OC352713 and with its registered office at CityPoint, One Ropemaker Street, London EC2Y 9SS, United Kingdom, as well as registered with the trade register kept with the Chamber of Commerce in Amsterdam, the Netherlands, with number 51088282 with registered office at the above address.  The word “partner” refers to a member of Simmons & Simmons LLP or an employee or consultant with equivalent standing and qualifications. A list of members and other partners and their professional qualifications is available for inspection at all our offices. Our terms of business, which contain a limitation of our liability, apply to all our services.

 

 

CONTENTS

 

	
1.
    	
Definitions
    	
1
    
	
 
    	
 
    	
 
    
	
2.
    	
Confidentiality of Information
    	
2
    
	
 
    	
 
    	
 
    
	
3.
    	
Further undertakings by the Recipient
    	
3
    
	
 
    	
 
    	
 
    
	
5.
    	
No representation
    	
3
    
	
 
    	
 
    	
 
    
	
6.
    	
Amendments
    	
4
    
	
 
    	
 
    	
 
    
	
7.
    	
Inside information
    	
4
    
	
 
    	
 
    	
 
    
	
8.
    	
Term
    	
4
    
	
 
    	
 
    	
 
    
	
9.
    	
Governing law and Jurisdiction
    	
4
    

 

i

 

CONFIDENTIALITY AND STANDSTILL AGREEMENT

 

BETWEEN:

 

[(1)                            Amsterdam Molecular Therapeutics (AMT) Holding N.V. a public company (naamloze vennootschap), incorporated under the laws of the Netherlands with its registered office (zetel) in Amsterdam, and its business address at Meibergdreff 61,105 BA, Amsterdam Zuidoost and registered with the Dutch Commercial Register (Handelsregister) of Amsterdam under number 33301321 (“Company”); and

 

(2)                                Forbion I Management B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid)], incorporated under the laws of the Netherlands with its registered office (zetel) in Amsterdam, and its business address at Gooimeer 2-35, 1411 DC Naarden and registered with the Dutch Commercial Register (Handelsregister) of Amsterdam under number 34249888 (the “Recipient”).

 

The Company and the Recipient, jointly the “Parties”.

 

WHEREAS:

 

(A)                               the Recipient is interested in investigating the possibilities of pursuing a transaction (“Transaction”) involving certain or all assets of the Company or an alternative transaction regarding the Company and its subsidiaries (all together, including any affiliates, hereinafter referred to as the “Group”), in the context of which the Recipient may receive certain Information (as defined herein);

 

(B)                               in consideration of the Company’s willingness to make Information available to the Recipient and in order to enable the Recipient to evaluate the Transaction, the Recipient hereby commits to keep the Information confidential and to comply with the standstill provisions, all in accordance with this Agreement.

 

DECLARE TO HAVE AGREED AS FOLLOWS:

 

1.                                     Definitions

 

1.1                               In this Agreement the following capitalised words shall have the following meanings:

 

“Agreement” means this Confidentiality and Standstill Agreement;

 

“Information” means any information or data relating to the Transaction, the Group, the Group’s assets and liabilities, the shareholders of the Company and/or any of their respective affiliates, whether received orally, in writing, electronically, visually or in any other form and whether before or after the date of this Agreement, together with all analyses, memoranda, reports, documents, data or information which contain or reflect information or data as aforementioned. “Information” does not include any information which:

 

(A)                               was, as at the date of its disclosure to the Recipient, public knowledge, or which subsequently to the date of its disclosure, becomes public knowledge other than by reason of any breach of this Agreement;

 

(B)                               is lawfully obtained by the Recipient through any other source and without any express or implicit obligation of confidentiality.

 

1

 

(C)                               is required to be disclosed by (i) any court of competent jurisdiction or any competent judicial, governmental, supervisory or regulatory body, or (ii) the rules of any stock exchange on which the shares or other securities of the Company are listed; and

 

(D)                               is disclosed with prior written consent of the Company, subject to the conditions set forth in such written consent.

 

“Group” as defined above;

 

“Company” as defined above;

 

“Inside Information” as defined in clause 6.1;

 

“Recipient Representative” as defined in clause 2.6;

 

“Parties” as defined above; and

 

“Transaction” as defined above.

 

1.2                               In this Agreement a reference to the Group, the Recipient or any of their respective affiliates shall include a reference to the managing directors, supervisory directors, shareholders, employees and advisers of the Group, the Recipient and their respective affiliates.

 

1.3                               In this Agreement any reference to a person includes a reference to persons and corporate bodies including partnerships.

 

1.4                               In this Agreement a reference to an “affiliate” shall be construed as a reference to a group company within the meaning of section 2:24b of the Dutch Civil Code.

 

2.                                     Confidentiality of Information

 

2.1                               The Recipient shall hold the Information strictly confidential and shall not without the prior written consent of the Company:

 

(A)                              reveal (or cause to be revealed), disclose (or cause to be disclosed), make (or cause to be made) available or publish (or cause to be published) the Information, or any part thereof, in any shape, form or manner; or

 

(B)                              use (or cause to be used) or make (or cause to made) use of the Information, or any part thereof, for any purpose other than in connection with the Transaction;

 

it being understood that Information obtained by any Recipient Representative that holds a position with the Company, whether as supervisory board member, advisor, or otherwise, may continue to be used by such persion in fulfilling his (statutory) obligations via-à-vis the Company in ordinary course.

 

2

 

2.2                               The Recipient shall keep confidential and not disclose to anyone the existence and/or nature of the negotiations in relation to the Transaction, the existence of this Agreement or the fact that the Information has been made available.

 

2.3                               If the Recipient becomes aware of the confidentiality of Information having been breached or is threatened to be breached, it shall immediately notify the Company of the same and in consultation with the Company take all necessary steps to mitigate the effects of such (threatened) breach.

 

2.4                               The Recipient shall immediately inform (to the extent permitted by law) the Company of any requirement to disclose or request or order for any disclosure referred to in clause 1.1(C) and inform the Company of the full circumstances in relation thereto.

 

2.5                              The restrictions on disclosure and use set out in this Agreement apply similarly to all documents and (computerised) data prepared by or on behalf of the Recipient containing or based on the Information.

 

2.6                               The restrictions on disclosure and use set out in this Agreement apply similarly to the Recipient’s (ultimate) parent compan(y)(ies), its and their affiliates, advisers, agents, representatives, directors and employees (each such party a “Recipient Representative”).

 

2.7                               The Recipient shall be allowed to make the Information available to a Recipient Representative solely on a need to know basis and provided that these persons are bound by at least equivalent confidentiality obligations and restrictions towards the Recipient. The Recipient shall inform each such Recipient Representative to whom the Information may be made available and to whom Information is disclosed about the restrictions as to the use and the disclosure of the Information set out herein and shall ensure that each such Recipient Representative shall observe those restrictions.

 

2.8                               The Recipient is responsible for any breach of this Agreement, which includes a breach by or resulting from a Recipient Representative’s breach of any such equivalent confidentiality obligations and restrictions.

 

3.                                     Further undertakings by the Recipient

 

3.1                               The Recipient shall not, and shall procure that the Recipient Representatives which were provided with Information shall not, without the prior written consent of the Company, directly or indirectly, contact, solicit or entice away any employee (including directors and managers) of the Company or its subsidiaries or affiliates.

 

3.2                               At the earlier event of the termination of this Agreement or the termination of the discussions in respect of the Transaction, the Recipient shall (and shall cause the Recipient Representative’s to) return to the Company, at the Company’s first request, all Information and all copies thereof. In addition, the Recipient shall (and shall cause the Recipient Representative’s to) destroy (or produce evidence of the destruction of) any documents or data (including data held in computerised forms) which contain or are based on the Information.

 

4.                                     No representation

 

4.1                               The Recipient acknowledges and agrees that neither the Company, nor any of its officers, employees or advisers (i) make any representation or warranty, express or implied, as to, or assume any responsibility for, the accuracy, reliability or completeness of any of the Information or the assumption on which it is based or (ii) shall be under any obligation to update or correct any inaccuracy in the Information or otherwise be liable to the Recipient or any other person (including any Recipient Representative) in respect to the Information.

 

3

 

5.                                     Amendments

 

The terms of this Agreement and the obligations under this Agreement of the Parties may only be amended or modified by written agreement between Parties.

 

6.                                     Inside information and Standstill

 

6.1                               The Recipient agrees and acknowledges that some or all of the Information provided, is or may qualify as or contain inside information (voorwetenschap) as defined in section 5:53 of the Dutch Act on Financial Supervision (Wet op het financieel toezicht) (“Inside Information”) and that the use of such Inside Information may be regulated or prohibited by applicable legislation relating to insider dealing.

 

7.                                     Term

 

7.1                               Unless otherwise provided in this Agreement, and except as otherwise required by applicable laws, this Agreement will remain effective for a period of six months after the date hereof, unless amended or terminated earlier in writing by mutual consent between the Parties hereto.

 

7.2                               Subject to clause 7.1, the obligations in this Agreement are continuing and, in particular, shall survive the termination of any discussions or negotiations between the Parties.

 

8.                                     General provisions

 

8.1                               The Parties to this Agreement waive their rights, if any, to annul (vernietigen), (partly) rescind, (partly) dissolve (ontbinden) or cancel this Agreement, or to request annulment, (partly) rescission, (partly) dissolution or cancellation of this Agreement, including on the basis of section 6:228 or 6:265 of the Dutch Civil Code.

 

8.2                               This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same document and that each signatory may deliver a signed copy of this Agreement by fax and that any such faxed copy shall be deemed to be an original for all purposes.

 

9.                                     Governing law and Jurisdiction

 

9.1                               This Agreement and any contractual and non contractual obligations arising therefrom shall be governed exclusively by Dutch law.

 

9.2                               All disputes arising out of or in connection with this Agreement shall be settled by the competent court in Amsterdam, the Netherlands, subject to appeal and appeal in the second instance. The Parties irrevocably waive any rights that they may have or acquire to object to the jurisdiction of these courts.

 

***

 

4

 

	
Amsterdam Molecular
    	
 
    	
 
    	
 
    	
 
    
	
Therapeutics (AMT) Holding N.V.
    	
 
    	
Forbion I Management B.V.
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
/s/L.P.A Bergstein
    	
 
    	
/s/M.A. van Osch
    
	
Name:
    	
 
    	
Name: L.P.A. Bergstein
    	
 
    	
M.A. van Osch
    
	
Title:
    	
 
    	
Title: Director
    	
 
    	
Director
    
	
Date:
    	
 
    	
Date 22/12/11
    	
 
    	
22/12/11
    

 

5

 

SCHEDULE 2 — FAIRNESS OPINION

 

31

 

	

    	
Ernst &   Young LLP
    
	
1 More London   Place
    
	
London SE1 2AF
    
	
 
    
	
Tel: 020 7951   2000
    
	
Fax: 020 7951   1345
    
	
www.ey.com/uk
    

 

	
 
    	
 
    	
17   February 2012
    
	
The Special Committee of the Supervisory   Board
    	
Your ref:
    	
 
    
	
Amsterdam Molecular Therapeutics (AMT)   Holding N.V.
    	
Our ref:
    	
TAS/VBM/ST/SD
    
	
Meibergdreef 61
    	
 
    	
 
    
	
1105 BA Amsterdam
    	
Direct line:
    	
020 7951 4302
    
	
The Netherlands
    	
Email:
    	
staylor11@uk.ey.com
    

 

For the attention of F. Verdonck

 

Dear Sirs

 

Amsterdam Molecular Therapeutics (AMT) Holding N.V.

 

Related to the proposed transaction (the “Transaction”) to acquire the assets and liabilities of Amsterdam Molecular Therapeutics (AMT) Holding N.V. (“AMT” or the “Company”) in exchange for Depositary Receipts for Ordinary Shares issued by a Foundation Trust (Stichting Administratiekantoor) holding Ordinary Shares in the capital of uniQure B.V., the Supervisory Board and Management Board of AMT have requested Ernst & Young Transaction Advisory Services, as independent adviser, to give its opinion as to whether the transaction is fair and reasonable so far as shareholders are concerned. The Transaction would include the Company’s manufacturing facility, portfolio of intellectual property rights and AMT’s employees.  The consideration and other terms relating to the Transaction are described in the shareholder circular dated 17 February 2012 (the “Shareholder Circular”).

 

In arriving at our opinion as set out below, we have, amongst other things:

 

1. Reviewed certain publicly available business and financial information relating to the Company that we deemed to be relevant;

 

2. Reviewed certain information, including financial forecasts relating to AMT’s business, the future earnings and cash flow expectations, details of the business assets and liabilities, and prospects for the commercialisation of certain gene therapy related products, as provided to us by the Company;

 

3. Conducted discussions with members of senior management of the Company concerning the matters described in points 1 and 2 above, as well as the corporate plans, financing strategies and the future financial prospects before and after giving effect to the Transaction;

 

4. Reviewed a copy of the final draft of the Shareholders Circular dated 17 February 2012;

 

 

5. Reviewed the market price and recent historical share price trends for the outstanding shares of the Company and compared them with those of certain publicly traded companies that we deemed to be relevant;

 

6. Reviewed the results of operations of the Company and compared them with those of certain publicly traded companies that we deemed to be relevant;

 

7. Compared the proposed financial terms of the Transaction with the financial terms of certain other transactions that we deemed to be relevant;

 

8. Performed certain valuation analysis related to the potential future cashflows pertaining to the major research and development product assets of the Company;

 

9. Held discussions with representatives of the Company’s financial adviser and legal adviser; and

 

10. Reviewed such other financial information and taken into account such other matters as we deemed necessary, including our assessment of general economic, market and financial conditions.

 

In preparing our opinion, we have assumed and relied on the accuracy and completeness of all information supplied or otherwise made available to us, discussed with or reviewed by us, or publicly available.  We have not assumed any responsibility for independently verifying such information. In addition, we have not undertaken an independent evaluation or appraisal of any of the assets or liabilities of the Company, or indeed any of the proposed Investors, or been provided with any such evaluation or appraisal nor have we evaluated the solvency or fair value of the Company or any of the Investors themselves under any laws relating to insolvency, bankruptcy, or any similar matters.

 

Furthermore, we have not assumed any obligation to conduct any physical on-site inspections of AMT’s properties or manufacturing facilities.

 

In providing this opinion, we have assumed that the Transaction will be completed on the terms described in the draft Shareholders Circular reviewed by us.  With respect to the financial forecast information furnished to or discussed with us by the Company, we have assumed that it has been reasonably and diligently prepared and reflects the contemporaneous estimates, judgment and views of the Company’s management as to the expected future financial performance of AMT.

 

We have assumed that in the course of obtaining the necessary regulatory or other consents or approvals (contractual or otherwise) for the Transaction to proceed, no restrictions, including any divestiture requirements or amendments or modifications, will be imposed that will have a material adverse effect on the contemplated benefits of the Transaction.

 

In connection with the preparation of this opinion, we have not been authorised by the Company to solicit, nor have we solicited, third-party indications of interest for the acquisition of all or any part of the Company.

 

Our opinion is based upon market, economic, financial and other conditions as they exist, and on the information made available to us, as of the date of this letter.

 

We will receive a fee from the Company for our services, none of which is contingent upon the completion of the Transaction.  We have not provided financial advisory or financing services to the Company, but may do so and may receive fees for the rendering of such services in the future.

 

This opinion is solely for the use and benefit of the Special Committee of the Supervisory Board of the Company in its evaluation of the Transaction and shall not be used for any other purpose whatsoever.  This opinion is not intended to be relied upon or confer any rights or remedies upon

 

 

any creditor or employee. This opinion shall not, in whole or in part, be disclosed, disseminated, summarised or referred to, for any purpose other than for the purpose of public disclosure within the final Shareholders Circular related to this Transaction.

 

Our opinion does not address the merits of the decision by the Company to recommend the Transaction and does not constitute a recommendation to any shareholders as to how they should vote on the proposed Transaction.

 

On the basis of the above, we are of the opinion that, as of the date of this letter, the Transaction is fair and reasonable so far as AMT shareholders are concerned.

 

	
 
    	
 
    
	

    	
 
    
	
 
    	
 
    
	
Ernst & Young LLP
    	
 
    
	
United Kingdom
    	
 
    

 

 

SCHEDULE 3 — IPR AND FURTHER ASSETS AND LIABILITIES

 

Part 1 — Intellectual Property Rights

 

“Intellectual Property Rights” means the intellectual property rights of the Group in relation to the Business, such as but not limited to (a) patents, trade marks, service marks, registered designs, trade, business and company names, internet domain names and e-mail addresses, unregistered trade marks and service marks, copyrights, database rights, know how, rights in designs and inventions and applications and rights to apply for any of those rights; (b) the rights to sue for past infringements of any of the foregoing rights, including those set out in the table below.

 

LIST OF TRADEMARKS

 

	
 
    	
 
    	
Catchword
    	
 
    	
Type
    	
 
    	
Country
    	
 
    	
Classes
    	
 
    	
Appl.No.
    	
 
    	
Appl.date
    	
 
    	
Reg.No.
    	
 
    	
Reg.date
    	
 
    	
Ren.date
    	
 
    	
Applicant
    	
 
    	
Status
    	
 
    	
Case No.
    	
 
    	
Watch
    
	
1.
    	
 
    	
AMT
    	
 
    	
Wordmark
    	
 
    	
BX
    	
 
    	
01, 05, 42
    	
 
    	
996846
    	
 
    	
13-09-01.
    	
 
    	
696184
    	
 
    	
13-09-01.
    	
 
    	
13-09-11.
    	
 
    	
AMT B.V.
    	
 
    	
Registered
    	
 
    	
T17138BX00
    	
 
    	
Yes
    
	
2.
    	
 
    	
AMT
    	
 
    	
Wordmark
    	
 
    	
CA
    	
 
    	
01, 05, 42
    	
 
    	
1130879
    	
 
    	
12-02-02.
    	
 
    	
630501
    	
 
    	
19-01-05.
    	
 
    	
19-01-20.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T17138CA00
    	
 
    	
Yes
    
	
3.
    	
 
    	
AMT
    	
 
    	
Wordmark
    	
 
    	
EU
    	
 
    	
01, 05, 42
    	
 
    	
2573137
    	
 
    	
11-02-02.
    	
 
    	
2573137
    	
 
    	
03-07-03.
    	
 
    	
11-02-22.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T17138EU00
    	
 
    	
Yes
    
	
4.
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
BX
    	
 
    	
01, 05, 42
    	
 
    	
996845
    	
 
    	
13-09-01.
    	
 
    	
700080
    	
 
    	
13-09-01.
    	
 
    	
13-09-11.
    	
 
    	
AMT B.V.
    	
 
    	
Registered
    	
 
    	
T17139BX00
    	
 
    	
Yes
    
	
5.
    	
 
    	
AMT
    	
 
    	
Wordmark
    	
 
    	
CA
    	
 
    	
01, 05, 42, 44
    	
 
    	
1478301
    	
 
    	
23-04-10.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T55829CA00
    	
 
    	
Yes
    

 

1

 

	
6.
    	
 
    	
AMT
    	
 
    	
Wordmark
    	
 
    	
EU
    	
 
    	
01, 05, 42, 44
    	
 
    	
8640237
    	
 
    	
26-10-09.
    	
 
    	
8640237
    	
 
    	
10-05-10.
    	
 
    	
26-10-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T55829EU00
    	
 
    	
Yes
    
	
7.
    	
 
    	
AMT
    	
 
    	
Wordmark
    	
 
    	
US
    	
 
    	
01, 05, 42
    	
 
    	
85/021857
    	
 
    	
23-04-10.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T55829US00
    	
 
    	
Yes
    
	
8.
    	
 
    	
AMT
    	
 
    	
Wordmark
    	
 
    	
US
    	
 
    	
44
    	
 
    	
85/368007
    	
 
    	
11-07-11.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T55829US01
    	
 
    	
Yes
    
	
9.
    	
 
    	
AMT
    	
 
    	
Wordmark
    	
 
    	
CH (WO)
    	
 
    	
01, 05, 42, 44
    	
 
    	
8640237-01
    	
 
    	
23-04-10.
    	
 
    	
1040425
    	
 
    	
23-04-10.
    	
 
    	
23-04-20.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T55829WO00
    	
 
    	
Yes
    
	
10. 
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
CH
    	
 
    	
05
    	
 
    	
536152008
    	
 
    	
06-04-09.
    	
 
    	
587323
    	
 
    	
09-06-09.
    	
 
    	
06-04-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56005CH00
    	
 
    	
No
    
	
11. 
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
IL
    	
 
    	
05
    	
 
    	
209906
    	
 
    	
24-03-08.
    	
 
    	
209906
    	
 
    	
07-02-10.
    	
 
    	
24-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56005IL00
    	
 
    	
No
    

 

2

 

	
12.
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
IS
    	
 
    	
05
    	
 
    	
10692009
    	
 
    	
22-04-09.
    	
 
    	
3772009
    	
 
    	
02-06-09.
    	
 
    	
02-06-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56005IS00
    	
 
    	
No
    
	
13.
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
JO
    	
 
    	
05
    	
 
    	
100494
    	
 
    	
23-04-08.
    	
 
    	
100494
    	
 
    	
23-04-08.
    	
 
    	
23-04-18.
    	
 
    	
Amsterdam Molecular Therapeutics   (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56005JO00
    	
 
    	
No
    
	
14.
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
NO
    	
 
    	
05
    	
 
    	
200905089
    	
 
    	
21-04-09.
    	
 
    	
251774
    	
 
    	
14-07-09.
    	
 
    	
14-07-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56005NO00
    	
 
    	
No
    
	
15.
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
TR
    	
 
    	
05
    	
 
    	
200925333
    	
 
    	
18-05-09.
    	
 
    	
200925333
    	
 
    	
04-05-10.
    	
 
    	
18-05-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56005TR00
    	
 
    	
No
    
	
16.
    	
 
    	
 
    	
 
    	
Logotype
    	
 
    	
EU
    	
 
    	
01, 05, 42, 44
    	
 
    	
8640252
    	
 
    	
26-10-09.
    	
 
    	
8640252
    	
 
    	
10-05-10.
    	
 
    	
26-10-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T55830EU00
    	
 
    	
Yes
    

 

3

 

	
17.
    	
 
    	
 
    	
 
    	
Logotype
    	
 
    	
US
    	
 
    	
01, 05, 42, 44
    	
 
    	
85/021908
    	
 
    	
23-04-10.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T55830US00
    	
 
    	
Yes
    
	
18.
    	
 
    	
 
    	
 
    	
Wordmark
    	
 
    	
EU
    	
 
    	
01, 05, 42, 44
    	
 
    	
9599937
    	
 
    	
15-12-10.
    	
 
    	
9599937
    	
 
    	
26-04-11.
    	
 
    	
15-12-20.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56839EU00
    	
 
    	
Indirect watch
    
	
19.
    	
 
    	
 
    	
 
    	
Wordmark
    	
 
    	
US
    	
 
    	
01, 05, 42, 44
    	
 
    	
85/338438
    	
 
    	
06-06-11.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T56839US00
    	
 
    	
Indirect watch
    
	
20.
    	
 
    	
 
    	
 
    	
Wordmark
    	
 
    	
JP (WO)
    	
 
    	
05
    	
 
    	
9599937_01
    	
 
    	
03-06-11.
    	
 
    	
1089500
    	
 
    	
03-06-11.
    	
 
    	
03-06-21.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56839WO00
    	
 
    	
Indirect watch
    
	
21.
    	
 
    	
 
    	
 
    	
Wordmark
    	
 
    	
TR (WO)
    	
 
    	
05
    	
 
    	
9599937_01
    	
 
    	
03-06-11.
    	
 
    	
1089500
    	
 
    	
03-06-11.
    	
 
    	
03-06-21.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56839WO00
    	
 
    	
Indirect watch
    

 

4

 

	
22.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
AE
    	
 
    	
05
    	
 
    	
113972
    	
 
    	
03-06-08.
    	
 
    	
150481
    	
 
    	
09-12-11.
    	
 
    	
03-06-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004AE00
    	
 
    	
No
    
	
23.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
BH
    	
 
    	
05
    	
 
    	
64727
    	
 
    	
18-03-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular Therapeutics   (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56004BH00
    	
 
    	
No
    
	
24.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
CA
    	
 
    	
5
    	
 
    	
1388257
    	
 
    	
20-03-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T56004CA00
    	
 
    	
No
    
	
25.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
IR
    	
 
    	
05
    	
 
    	
86122678
    	
 
    	
18-03-08.
    	
 
    	
157479
    	
 
    	
14-09-08.
    	
 
    	
18-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004IR00
    	
 
    	
No
    
	
26.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
JP
    	
 
    	
05
    	
 
    	
2008023029
    	
 
    	
27-03-08.
    	
 
    	
5343913
    	
 
    	
06-08-10.
    	
 
    	
06-08-20.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56004JP00
    	
 
    	
No
    
	
27.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
LB
    	
 
    	
05
    	
 
    	
2449
    	
 
    	
08-04-08.
    	
 
    	
116062
    	
 
    	
24-04-08.
    	
 
    	
24-04-23.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004LB00
    	
 
    	
No
    
	
28.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
LY
    	
 
    	
05
    	
 
    	
17093
    	
 
    	
05-02-09.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56004LY00
    	
 
    	
No
    
	
29.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
MA
    	
 
    	
05
    	
 
    	
118083
    	
 
    	
19-06-08.
    	
 
    	
118083
    	
 
    	
17-11-08.
    	
 
    	
19-06-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004MA00
    	
 
    	
No
    
	
30.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
OM
    	
 
    	
05
    	
 
    	
49398
    	
 
    	
19-03-08.
    	
 
    	
49398
    	
 
    	
11-08-09.
    	
 
    	
19-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004OM00
    	
 
    	
No
    

 

5

 

	
31.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
QA
    	
 
    	
05
    	
 
    	
50165
    	
 
    	
03-04-08.
    	
 
    	
50165
    	
 
    	
20-03-11.
    	
 
    	
03-04-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004QA00
    	
 
    	
No
    
	
32.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
RU
    	
 
    	
05
    	
 
    	
2008707490
    	
 
    	
14-03-08.
    	
 
    	
381651
    	
 
    	
16-06-09.
    	
 
    	
14-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004RU00
    	
 
    	
No
    
	
33.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
SY
    	
 
    	
05
    	
 
    	
3814
    	
 
    	
22-04-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56004SY00
    	
 
    	
No
    
	
34.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
TN
    	
 
    	
05
    	
 
    	
EE080755
    	
 
    	
19-03-08.
    	
 
    	
EE080755
    	
 
    	
26-01-10.
    	
 
    	
19-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004TN00
    	
 
    	
No
    
	
35.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
US
    	
 
    	
05
    	
 
    	
77/421590
    	
 
    	
13-03-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56004US00
    	
 
    	
No
    
	
36.
    	
 
    	
DELIVERING CURE
    	
 
    	
Wordmark
    	
 
    	
ZA
    	
 
    	
05
    	
 
    	
200805836
    	
 
    	
14-03-08.
    	
 
    	
200805836
    	
 
    	
14-03-08.
    	
 
    	
14-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56004ZA00
    	
 
    	
No
    
	
37.
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
EU
    	
 
    	
05, 44
    	
 
    	
8640609
    	
 
    	
26-10-09.
    	
 
    	
8640609
    	
 
    	
10-05-10.
    	
 
    	
26-10-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T55831EU00
    	
 
    	
Yes
    
	
38.
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
US
    	
 
    	
05, 44
    	
 
    	
85/021938
    	
 
    	
23-04-10.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T55831US00
    	
 
    	
Yes
    

 

6

 

	
39.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
AE
    	
 
    	
05
    	
 
    	
101941
    	
 
    	
31-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56001AE00
    	
 
    	
Yes
    
	
40.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
AU
    	
 
    	
05
    	
 
    	
1176048
    	
 
    	
14-05-07.
    	
 
    	
1176048
    	
 
    	
12-12-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001AU00
    	
 
    	
Yes
    
	
41.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
BH
    	
 
    	
05
    	
 
    	
62689
    	
 
    	
07-01-08.
    	
 
    	
62689
    	
 
    	
07-01-08.
    	
 
    	
07-01-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001BH00
    	
 
    	
Yes
    
	
42.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
CA
    	
 
    	
5
    	
 
    	
1355754
    	
 
    	
16-07-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T56001CA00
    	
 
    	
Yes
    
	
43.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
CH
    	
 
    	
05
    	
 
    	
551392007
    	
 
    	
14-05-07.
    	
 
    	
562178
    	
 
    	
11-09-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56001CH00
    	
 
    	
Yes
    
	
44.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
DZ
    	
 
    	
05
    	
 
    	
72791
    	
 
    	
24-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56001DZ00
    	
 
    	
Yes
    
	
45.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
EG
    	
 
    	
05
    	
 
    	
208229
    	
 
    	
22-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56001EG00
    	
 
    	
Yes
    
	
46.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
EU
    	
 
    	
05, 44
    	
 
    	
5901269
    	
 
    	
01-05-07.
    	
 
    	
5901269
    	
 
    	
14-05-09.
    	
 
    	
01-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56001EU00
    	
 
    	
Yes
    
	
47.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
IL
    	
 
    	
05
    	
 
    	
204800
    	
 
    	
21-10-07.
    	
 
    	
204800
    	
 
    	
11-08-09.
    	
 
    	
21-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001IL00
    	
 
    	
Yes
    

 

7

 

	
48.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
IS
    	
 
    	
05
    	
 
    	
14642007
    	
 
    	
14-05-07.
    	
 
    	
8122007
    	
 
    	
04-07-07.
    	
 
    	
04-07-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001IS00
    	
 
    	
Yes
    
	
49.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
JO
    	
 
    	
05
    	
 
    	
99133
    	
 
    	
24-10-07.
    	
 
    	
99133
    	
 
    	
01-05-07.
    	
 
    	
01-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001JO00
    	
 
    	
Yes
    
	
50.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
JP
    	
 
    	
05
    	
 
    	
2007054257
    	
 
    	
30-05-07.
    	
 
    	
5088657
    	
 
    	
02-11-07.
    	
 
    	
02-11-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56001JP00
    	
 
    	
Yes
    
	
51.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
LB
    	
 
    	
05
    	
 
    	
6612
    	
 
    	
23-10-07.
    	
 
    	
113370
    	
 
    	
25-10-07.
    	
 
    	
25-10-22.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001LB00
    	
 
    	
Yes
    
	
52.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
LY
    	
 
    	
05
    	
 
    	
16593
    	
 
    	
22-12-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56001LY00
    	
 
    	
Yes
    
	
53.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
MA
    	
 
    	
05
    	
 
    	
113550
    	
 
    	
23-10-07.
    	
 
    	
113550
    	
 
    	
23-10-07.
    	
 
    	
23-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001MA00
    	
 
    	
Yes
    
	
54.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
NO
    	
 
    	
05
    	
 
    	
200705606
    	
 
    	
15-05-07.
    	
 
    	
241553
    	
 
    	
19-10-07.
    	
 
    	
19-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001NO00
    	
 
    	
Yes
    
	
55.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
NZ
    	
 
    	
05
    	
 
    	
768310
    	
 
    	
14-05-07.
    	
 
    	
768310
    	
 
    	
15-11-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001NZ00
    	
 
    	
Yes
    
	
56.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
OM
    	
 
    	
05
    	
 
    	
47462
    	
 
    	
22-10-07.
    	
 
    	
47462
    	
 
    	
24-08-08.
    	
 
    	
22-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001OM00
    	
 
    	
Yes
    

 

8

 

	
57.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
QA
    	
 
    	
05
    	
 
    	
47253
    	
 
    	
31-10-07.
    	
 
    	
47253
    	
 
    	
31-12-09.
    	
 
    	
31-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001QA00
    	
 
    	
Yes
    
	
58.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
RU
    	
 
    	
05
    	
 
    	
2008707340
    	
 
    	
13-03-08.
    	
 
    	
377215
    	
 
    	
20-04-09.
    	
 
    	
13-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001RU00
    	
 
    	
Yes
    
	
59.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
SA
    	
 
    	
05
    	
 
    	
125692
    	
 
    	
12-01-08.
    	
 
    	
1156/45
    	
 
    	
25-04-10.
    	
 
    	
12-09-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001SA00
    	
 
    	
Yes
    
	
60.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
SY
    	
 
    	
05
    	
 
    	
4268
    	
 
    	
28-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56001SY00
    	
 
    	
Yes
    
	
61.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
TN
    	
 
    	
05
    	
 
    	
EE072667
    	
 
    	
24-10-07.
    	
 
    	
EE072667
    	
 
    	
19-05-09.
    	
 
    	
24-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001TN00
    	
 
    	
Yes
    
	
62.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
TR
    	
 
    	
05
    	
 
    	
2007026778
    	
 
    	
17-05-07.
    	
 
    	
200726778
    	
 
    	
17-05-07.
    	
 
    	
17-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001TR00
    	
 
    	
Yes
    
	
63.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
US
    	
 
    	
05
    	
 
    	
77/179356
    	
 
    	
11-05-07.
    	
 
    	
3972244
    	
 
    	
07-06-11.
    	
 
    	
07-06-21.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56001US00
    	
 
    	
Yes
    
	
64.
    	
 
    	
GLYBERA
    	
 
    	
Wordmark
    	
 
    	
ZA
    	
 
    	
05
    	
 
    	
200723919
    	
 
    	
19-10-07.
    	
 
    	
2007/23919
    	
 
    	
19-10-07.
    	
 
    	
19-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56001ZA00
    	
 
    	
Yes
    
	
65.
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
EU
    	
 
    	
05, 44
    	
 
    	
8640641
    	
 
    	
26-10-09.
    	
 
    	
8640641
    	
 
    	
10-05-10.
    	
 
    	
26-10-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T55832EU00
    	
 
    	
Indirect watch
    

 

9

 

	
66.
    	
 
    	

    	
 
    	
Logotype
    	
 
    	
US
    	
 
    	
05, 44
    	
 
    	
85/021985
    	
 
    	
23-04-10.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T55832US00
    	
 
    	
Indirect watch
    
	
67.
    	
 
    	
LPLCHIP
    	
 
    	
Wordmark
    	
 
    	
CA
    	
 
    	
1, 10, 42, 44, 5, 9
    	
 
    	
1474070
    	
 
    	
22-03-10.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T55770CA00
    	
 
    	
Yes
    
	
68.
    	
 
    	
LPLCHIP
    	
 
    	
Wordmark
    	
 
    	
EU
    	
 
    	
01, 05, 09, 10, 42, 44
    	
 
    	
8590911
    	
 
    	
02-10-09.
    	
 
    	
8590911
    	
 
    	
31-05-10.
    	
 
    	
02-10-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T55770EU00
    	
 
    	
Yes
    
	
69.
    	
 
    	
LPLCHIP
    	
 
    	
Wordmark
    	
 
    	
US
    	
 
    	
1, 5, 9
    	
 
    	
77/964892
    	
 
    	
22-03-10.
    	
 
    	
3972502
    	
 
    	
07-06-11.
    	
 
    	
07-06-21.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T55770US00
    	
 
    	
Yes
    
	
70.
    	
 
    	
LPLCHIP
    	
 
    	
Wordmark
    	
 
    	
CH (WO)
    	
 
    	
01, 05, 09, 10
    	
 
    	
8590911-01
    	
 
    	
06-04-10.
    	
 
    	
1036745
    	
 
    	
06-04-10.
    	
 
    	
06-04-20.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T55770WO00
    	
 
    	
Yes
    
	
71.
    	
 
    	
LPLCHIP
    	
 
    	
Wordmark
    	
 
    	
IS (WO)
    	
 
    	
01, 05, 09, 10
    	
 
    	
8590911-01
    	
 
    	
06-04-10.
    	
 
    	
1036745
    	
 
    	
06-04-10.
    	
 
    	
06-04-20.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T55770WO00
    	
 
    	
Yes
    
	
72.
    	
 
    	
LPLCHIP
    	
 
    	
Wordmark
    	
 
    	
NO (WO)
    	
 
    	
01, 05, 09, 10
    	
 
    	
8590911-01
    	
 
    	
06-04-10.
    	
 
    	
1036745
    	
 
    	
06-04-10.
    	
 
    	
06-04-20.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T55770WO00
    	
 
    	
Yes
    
	
73.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
AE
    	
 
    	
05
    	
 
    	
101942
    	
 
    	
31-10-07.
    	
 
    	
100927
    	
 
    	
24-03-10.
    	
 
    	
31-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002AE00
    	
 
    	
Yes
    
	
74.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
AU
    	
 
    	
05
    	
 
    	
1176051
    	
 
    	
14-05-07.
    	
 
    	
1176051
    	
 
    	
12-12-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002AU00
    	
 
    	
Yes
    

 

10

 

	
75.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
BH
    	
 
    	
05
    	
 
    	
62690
    	
 
    	
07-01-08.
    	
 
    	
62690
    	
 
    	
07-01-08.
    	
 
    	
07-01-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002BH00
    	
 
    	
Yes
    
	
76.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
CA
    	
 
    	
5
    	
 
    	
1355761
    	
 
    	
16-07-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T56002CA00
    	
 
    	
Yes
    
	
77.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
CH
    	
 
    	
05
    	
 
    	
551382007
    	
 
    	
14-05-07.
    	
 
    	
562177
    	
 
    	
11-09-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56002CH00
    	
 
    	
Yes
    
	
78.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
DZ
    	
 
    	
05
    	
 
    	
72793
    	
 
    	
24-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56002DZ00
    	
 
    	
Yes
    
	
79.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
EG
    	
 
    	
05
    	
 
    	
208203
    	
 
    	
22-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56002EG00
    	
 
    	
Yes
    
	
80.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
EU
    	
 
    	
05
    	
 
    	
5901277
    	
 
    	
01-05-07.
    	
 
    	
5901277
    	
 
    	
10-04-08.
    	
 
    	
01-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56002EU00
    	
 
    	
Yes
    
	
81.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
IL
    	
 
    	
05
    	
 
    	
204915
    	
 
    	
23-10-07.
    	
 
    	
204915
    	
 
    	
11-08-09.
    	
 
    	
23-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002IL00
    	
 
    	
Yes
    
	
82.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
IR
    	
 
    	
05
    	
 
    	
86091403
    	
 
    	
08-12-07.
    	
 
    	
157475
    	
 
    	
14-09-08.
    	
 
    	
08-12-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002IR00
    	
 
    	
Yes
    
	
83.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
IS
    	
 
    	
05
    	
 
    	
14632007
    	
 
    	
14-05-07.
    	
 
    	
8112007
    	
 
    	
04-07-07.
    	
 
    	
04-07-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002IS00
    	
 
    	
Yes
    

 

11

 

	
84.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
JO
    	
 
    	
05
    	
 
    	
99366
    	
 
    	
24-10-07.
    	
 
    	
99366
    	
 
    	
14-01-09.
    	
 
    	
01-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002JO00
    	
 
    	
Yes
    
	
85.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
JP
    	
 
    	
05
    	
 
    	
2007054258
    	
 
    	
30-05-07.
    	
 
    	
5088658
    	
 
    	
02-11-07.
    	
 
    	
02-11-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56002JP00
    	
 
    	
Yes
    
	
86.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
LB
    	
 
    	
05
    	
 
    	
6622
    	
 
    	
23-10-07.
    	
 
    	
113434
    	
 
    	
30-10-07.
    	
 
    	
30-10-22.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002LB00
    	
 
    	
Yes
    
	
87.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
LY
    	
 
    	
05
    	
 
    	
16595
    	
 
    	
22-12-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56002LY00
    	
 
    	
Yes
    
	
88.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
MA
    	
 
    	
05
    	
 
    	
113551
    	
 
    	
23-10-07.
    	
 
    	
113551
    	
 
    	
23-10-07.
    	
 
    	
23-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002MA00
    	
 
    	
Yes
    
	
89.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
NO
    	
 
    	
05
    	
 
    	
200705604
    	
 
    	
15-05-07.
    	
 
    	
241558
    	
 
    	
22-10-07.
    	
 
    	
22-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002NO00
    	
 
    	
Yes
    
	
90.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
NZ
    	
 
    	
05
    	
 
    	
768309
    	
 
    	
14-05-07.
    	
 
    	
768309
    	
 
    	
12-02-09.
    	
 
    	
01-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002NZ00
    	
 
    	
Yes
    
	
91.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
OM
    	
 
    	
05
    	
 
    	
47461
    	
 
    	
22-10-07.
    	
 
    	
47461
    	
 
    	
30-05-09.
    	
 
    	
22-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002OM00
    	
 
    	
Yes
    
	
92.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
QA
    	
 
    	
05
    	
 
    	
47255
    	
 
    	
31-10-07.
    	
 
    	
47255
    	
 
    	
31-12-09.
    	
 
    	
31-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56002QA00
    	
 
    	
Yes
    

 

12

 

	
93.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
RU
    	
 
    	
05
    	
 
    	
2008707342
    	
 
    	
13-03-08.
    	
 
    	
381400
    	
 
    	
10-06-09.
    	
 
    	
13-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002RU00
    	
 
    	
Yes
    
	
94.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
SA
    	
 
    	
05
    	
 
    	
125693
    	
 
    	
12-01-08.
    	
 
    	
1171/48
    	
 
    	
19-06-10.
    	
 
    	
12-09-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002SA00
    	
 
    	
Yes
    
	
95.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
SY
    	
 
    	
05
    	
 
    	
4269
    	
 
    	
28-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56002SY00
    	
 
    	
Yes
    
	
96.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
TN
    	
 
    	
05
    	
 
    	
EE072666
    	
 
    	
24-10-07.
    	
 
    	
EE072666
    	
 
    	
19-05-09.
    	
 
    	
24-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002TN00
    	
 
    	
Yes
    
	
97.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
TR
    	
 
    	
05
    	
 
    	
2007026779
    	
 
    	
17-05-07.
    	
 
    	
200726779
    	
 
    	
17-05-07.
    	
 
    	
17-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002TR00
    	
 
    	
Yes
    
	
98.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
US
    	
 
    	
05
    	
 
    	
77/179357
    	
 
    	
11-05-07.
    	
 
    	
3703954
    	
 
    	
03-11-09.
    	
 
    	
03-11-19.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56002US00
    	
 
    	
Yes
    
	
99.
    	
 
    	
VECTIPRO
    	
 
    	
Wordmark
    	
 
    	
ZA
    	
 
    	
05
    	
 
    	
200723918
    	
 
    	
19-10-07.
    	
 
    	
2007/23918
    	
 
    	
19-10-07.
    	
 
    	
19-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56002ZA00
    	
 
    	
Yes
    
	
100.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
AE
    	
 
    	
05
    	
 
    	
101943
    	
 
    	
31-10-07.
    	
 
    	
100909
    	
 
    	
24-03-10.
    	
 
    	
31-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003AE00
    	
 
    	
Yes
    
	
101.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
AU
    	
 
    	
05
    	
 
    	
1176049
    	
 
    	
14-05-07.
    	
 
    	
1176049
    	
 
    	
12-12-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003AU00
    	
 
    	
Yes
    

 

13

 

	
102.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
BH
    	
 
    	
05
    	
 
    	
62691
    	
 
    	
07-01-08.
    	
 
    	
62691
    	
 
    	
07-01-08.
    	
 
    	
07-01-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003BH00
    	
 
    	
Yes
    
	
103.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
CA
    	
 
    	
5
    	
 
    	
1355762
    	
 
    	
16-07-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Pending
    	
 
    	
T56003CA00
    	
 
    	
Yes
    
	
104.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
CH
    	
 
    	
05
    	
 
    	
551982007
    	
 
    	
15-05-07.
    	
 
    	
562360
    	
 
    	
13-09-07.
    	
 
    	
15-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56003CH00
    	
 
    	
Yes
    
	
105.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
DZ
    	
 
    	
05
    	
 
    	
72792
    	
 
    	
24-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56003DZ00
    	
 
    	
Yes
    
	
106.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
EG
    	
 
    	
05
    	
 
    	
208231
    	
 
    	
22-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56003EG00
    	
 
    	
Yes
    
	
107.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
EU
    	
 
    	
05, 44
    	
 
    	
5901251
    	
 
    	
01-05-07.
    	
 
    	
5901251
    	
 
    	
22-01-09.
    	
 
    	
01-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56003EU00
    	
 
    	
Yes
    
	
108.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
IL
    	
 
    	
05
    	
 
    	
204799
    	
 
    	
21-10-07.
    	
 
    	
204799
    	
 
    	
11-04-09.
    	
 
    	
21-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003IL00
    	
 
    	
Yes
    
	
109.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
IR
    	
 
    	
05
    	
 
    	
86091401
    	
 
    	
08-12-07.
    	
 
    	
158201
    	
 
    	
14-09-08.
    	
 
    	
08-12-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003IR00
    	
 
    	
Yes
    
	
110.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
IS
    	
 
    	
05
    	
 
    	
14652007
    	
 
    	
14-05-07.
    	
 
    	
8132007
    	
 
    	
04-07-07.
    	
 
    	
04-07-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003IS00
    	
 
    	
Yes
    

 

14

 

	
111.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
JO
    	
 
    	
05
    	
 
    	
99208
    	
 
    	
24-10-07.
    	
 
    	
99208
    	
 
    	
03-03-09.
    	
 
    	
01-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003JO00
    	
 
    	
Yes
    
	
112.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
JP
    	
 
    	
05
    	
 
    	
2007054259
    	
 
    	
30-05-07.
    	
 
    	
5088659
    	
 
    	
02-11-07.
    	
 
    	
02-11-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) IP B.V.
    	
 
    	
Registered
    	
 
    	
T56003JP00
    	
 
    	
Yes
    
	
113.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
LB
    	
 
    	
05
    	
 
    	
6623
    	
 
    	
23-10-07.
    	
 
    	
113437
    	
 
    	
30-10-07.
    	
 
    	
30-10-22.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003LB00
    	
 
    	
Yes
    
	
114.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
LY
    	
 
    	
05
    	
 
    	
16594
    	
 
    	
22-12-08.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56003LY00
    	
 
    	
Yes
    
	
115.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
MA
    	
 
    	
05
    	
 
    	
113552
    	
 
    	
23-10-07.
    	
 
    	
113552
    	
 
    	
23-10-07.
    	
 
    	
23-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003MA00
    	
 
    	
Yes
    
	
116.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
NO
    	
 
    	
05
    	
 
    	
200705605
    	
 
    	
15-05-07.
    	
 
    	
241517
    	
 
    	
18-10-07.
    	
 
    	
18-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003NO00
    	
 
    	
Yes
    
	
117.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
NZ
    	
 
    	
05
    	
 
    	
768311
    	
 
    	
14-05-07.
    	
 
    	
768311
    	
 
    	
15-11-07.
    	
 
    	
14-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003NZ00
    	
 
    	
Yes
    
	
118.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
OM
    	
 
    	
05
    	
 
    	
47463
    	
 
    	
22-10-07.
    	
 
    	
47463
    	
 
    	
30-05-09.
    	
 
    	
22-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003OM00
    	
 
    	
Yes
    
	
119.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
QA
    	
 
    	
05
    	
 
    	
47254
    	
 
    	
31-10-07.
    	
 
    	
47254
    	
 
    	
31-12-09.
    	
 
    	
31-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003QA00
    	
 
    	
Yes
    

 

15

 

	
120.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
RU
    	
 
    	
05
    	
 
    	
2008707341
    	
 
    	
13-03-08.
    	
 
    	
394999
    	
 
    	
01-12-09.
    	
 
    	
13-03-18.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003RU00
    	
 
    	
Yes
    
	
121.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
SA
    	
 
    	
05
    	
 
    	
125694
    	
 
    	
12-01-08.
    	
 
    	
1171/49
    	
 
    	
19-06-10.
    	
 
    	
12-09-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003SA00
    	
 
    	
Yes
    
	
122.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
SY
    	
 
    	
05
    	
 
    	
4267
    	
 
    	
28-10-07.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Pending
    	
 
    	
T56003SY00
    	
 
    	
Yes
    
	
123.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
TN
    	
 
    	
05
    	
 
    	
EE072668
    	
 
    	
24-10-07.
    	
 
    	
EE072668
    	
 
    	
19-05-09.
    	
 
    	
24-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003TN00
    	
 
    	
Yes
    
	
124.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
TR
    	
 
    	
05
    	
 
    	
2007026780
    	
 
    	
17-05-07.
    	
 
    	
200726780
    	
 
    	
07-04-08.
    	
 
    	
17-05-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003TR00
    	
 
    	
Yes
    
	
125.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
US
    	
 
    	
05
    	
 
    	
77/179359
    	
 
    	
11-05-07.
    	
 
    	
3855311
    	
 
    	
05-10-10.
    	
 
    	
05-10-20.
    	
 
    	
 
    	
 
    	
Registered
    	
 
    	
T56003US00
    	
 
    	
Yes
    
	
126.
    	
 
    	
ZYAMTIN
    	
 
    	
Wordmark
    	
 
    	
ZA
    	
 
    	
05
    	
 
    	
200723917
    	
 
    	
19-10-07.
    	
 
    	
200723917
    	
 
    	
14-07-10.
    	
 
    	
19-10-17.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    	
 
    	
Registered
    	
 
    	
T56003ZA00
    	
 
    	
Yes
    

 

16

 

LIST OF PATENTS

 

	
No.
    	
 
    	
Description patent
    	
 
    	
Owned or Co-
   Owned by
    	
 
    	
AMT reference
   No
    	
 
    	
Date of filing
   provisional
   application
    	
 
    	
Patent number
    	
 
    	
[Other]
    
	
Strategic Partnerships/Licenses
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Lipoprotein lipase (LPL) variant therapeutics
    	
 
    	
Amsterdam Molecular Therapeutics B.V.
    	
 
    	
AMT-P101
    	
 
    	
24 June 1999
    	
 
    	
PCT/CA00/00762
    	
 
    	
 
    
	
 
    	
 
    	
IL-10 gene transfer to peripheral mononuclear cells
    	
 
    	
Amsterdam Molecular Therapeutics B.V.
    	
 
    	
AMT-P102
    	
 
    	
07 March 2002
    	
 
    	
PCT/NL03/00170
    	
 
    	
 
    
	
 
    	
 
    	
Treatment of non-alcoholic steatotic hepatitis (NASH)
    	
 
    	
Amsterdam Molecular Therapeutics B.V.
    	
 
    	
AMT-P103
    	
 
    	
20 June 2005
    	
 
    	
PCT/NL05/000446
    	
 
    	
 
    
	
 
    	
 
    	
Improved AAV vectors produced in insect cells
    	
 
    	
Amsterdam Molecular Therapeutics B.V.
    	
 
    	
AMT-P104
    	
 
    	
20 October 2005
    	
 
    	
PCT/NL06/050262
    	
 
    	
 
    
	
 
    	
 
    	
Vectors with modified initiation codons for the translation of   AAV-Rep78 useful for the production of AAV in insect cells
    	
 
    	
Amsterdam Molecular Therapeutics B.V.
    	
 
    	
AMT-P105
    	
 
    	
21 June 2006
    	
 
    	
PCT/NL07/050298
    	
 
    	
 
    
	
 
    	
 
    	
Use of replication machinery for improved protein production
    	
 
    	
Amsterdam Molecular Therapeutics B.V.
    	
 
    	
AMT-P106
    	
 
    	
19 September 2007
    	
 
    	
PCT/NL08/050613
    	
 
    	
 
    
	
 
    	
 
    	
Baculovirus vectors comprising repeated coding sequences with   different codon biases
    	
 
    	
Amsterdam Molecular Therapeutics B.V.
    	
 
    	
AMT-P107
    	
 
    	
26 July 2007
    	
 
    	
PCT/NL08/050512
    	
 
    	
 
    

 

17

 

LIST OF PATENTS

 

	
No.
    	
 
    	
Description patent
    	
 
    	
Owned or Co-
   Owned by
    	
 
    	
AMT reference
   No
    	
 
    	
Date of filing
   provisional
   application
    	
 
    	
Patent number
    	
 
    	
[Other]
    
	
 
    	
 
    	
Optimization of expression of parvoviral rep and cap proteins in   insect cells
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P108
    	
 
    	
19 February 2008
    	
 
    	
PCT/NL90/050076
    	
 
    	
 
    
	
 
    	
 
    	
Parvoviral capsids with incorporated Gly-Ala repeat region
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P109
    	
 
    	
17 June 2008
    	
 
    	
PCT/NL09/050352
    	
 
    	
 
    
	
 
    	
 
    	
Porphobilinogen deaminase gene therapy
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P110
    	
 
    	
29 September 2008
    	
 
    	
PCT/NL09/050584
    	
 
    	
 
    
	
 
    	
 
    	
Alanine-Glyoxylate aminotransferase therapeutics
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P111
    	
 
    	
30 January 2009
    	
 
    	
PCT/NL10/050044
    	
 
    	
 
    
	
 
    	
 
    	
Use of lipoprotein lipase (LPL) in therapy
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P112
    	
 
    	
18 May 2009
    	
 
    	
PCT/NL10/050294
    	
 
    	
 
    
	
 
    	
 
    	
Removal of contaminating viruses from AAV preparations
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P113
    	
 
    	
08 September 2011
    	
 
    	
11180594.1  

 

61/532,176
    	
 
    	
 
    
	
 
    	
 
    	
Modified snRNA for use in therapy
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P116
    	
 
    	
08 June 2011
    	
 
    	
PCT/IB11/050584
    	
 
    	
 
    

 

18

 

LIST OF PATENTS

 

	
No.
    	
 
    	
Description patent
    	
 
    	
Owned or Co-
   Owned by
    	
 
    	
AMT reference
   No
    	
 
    	
Date of filing
   provisional
   application
    	
 
    	
Patent number
    	
 
    	
[Other]
    
	
 
    	
 
    	
Mutated Rep encoding sequences for use in AAV production
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P117
    	
 
    	
11 March 2010
    	
 
    	
PCT/NL11/050170
    	
 
    	
 
    
	
 
    	
 
    	
Method for identifying variant Rep protein encoding nucleic acids
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P118
    	
 
    	
11 March 2010
    	
 
    	
PCT/NL11/050171
    	
 
    	
 
    
	
 
    	
 
    	
Monomeric duplex AAV vectors
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P119
    	
 
    	
01 April 2011
    	
 
    	
PCT/NL11/050221
    	
 
    	
 
    
	
 
    	
 
    	
Method for determining efficacy of therapy and determining presence or   risk of disease
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P120
    	
 
    	
02 June 2010
    	
 
    	
PCT?NL11/050399
    	
 
    	
 
    
	
 
    	
 
    	
Method for the preparation of cells
    	
 
    	
Amsterdam Molecular Therapeutics (AMT) IP B.V.
    	
 
    	
AMT-P121
    	
 
    	
31 March 2011
    	
 
    	
11160727.1  

 

61/470,033
    	
 
    	
 
    

 

Part 2 - Contracts

 

“Contracts” means all contracts entered into by the Group relating to the Business and all (existing and future) rights and obligations thereunder, including those set out in the table below, but excluding the Excluded Contracts.

 

19

 

LIST OF CONTRACTS

 

	
No.
    	
 
    	
Description agreement
    	
 
    	
Date
    	
 
    	
Parties
    	
 
    	
Change of Control
   as result of Kairos
    	
 
    	
Remarks
    	
 
    	
Outstanding items
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Strategic   Partnerships/Licenses
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1.
    	
 
    	
Collaboration with CIMA
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
a
    	
 
    	
license agreement
    	
 
    	
21-05-2010
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Certain provisions of old agreement are or may still be in force.
    	
 
    	
The 2005 Agreements, the 2007 Agreements, the Privileged Access   Agreement the Virus encode IGF License should be checked for CoC.
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
b
    	
 
    	
collaborative development agreement
    	
 
    	
21-05-2010
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Certain provisions of old agreement are or may still be in force.
    	
 
    	
The 2005 Agreements, the 2007 Agreements, the Privileged Access   Agreement the Virus encode IGF License should be checked for CoC.
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
2.
    	
 
    	
Collaboration with   ST. Jude:
    	
 
    	
 
    	
 
    	
AMT B.V.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
a
    	
 
    	
sponsored research agreement
    	
 
    	
07-07-2007
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of the State of New York apply
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
b
    	
 
    	
license agreement
    	
 
    	
07-07-2007
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of the State of New York apply
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
c
    	
 
    	
AMT technology agreement
    	
 
    	
07-07-2007
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of the State of New York apply
    	
 
    	
 
    

 

20

 

LIST OF CONTRACTS

 

	
No.
    	
 
    	
Description agreement
    	
 
    	
Date
    	
 
    	
Parties
    	
 
    	
Change of Control
   as result of Kairos
    	
 
    	
Remarks
    	
 
    	
Outstanding items
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
d
    	
 
    	
research license agreement
    	
 
    	
27-10-2009
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of the State of Tennessee apply
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
3.
    	
 
    	
Collaboration Children ́s Hospital of Philadelphia
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
a
    	
 
    	
Research collaboration agreement
    	
 
    	
[08-03-2007]
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of Commonwealth of Pennsylvania apply
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
b
    	
 
    	
License agreement
    	
 
    	
[29-03-2010]
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of Commonwealth of Pennsylvania apply
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
4.
    	
 
    	
La Sapienza – License and Sponsored Research Agreement
    	
 
    	
[09]-05-2009
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of England and Wales apply
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
5.
    	
 
    	
Non-exclusive   worldwide commercial sub-license agreement with AskBio [in relation to the   intra-muscular administration of Glybera® for LPLD].
    	
 
    	
03-09-2010
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of the State of New York apply
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
6.
    	
 
    	
Non-exclusive   worldwide commercial license agreement with Protein Sciences Corporation in   relation to the use of Spodoptera   Frugiperda cells in relation to the AAV vector used in the   manufacture of Glybera® for LPLD.
    	
 
    	
22-03-2007
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of the State of Connecticut
    	
 
    	
[DOUBLE CHECK]
    

 

21

 

LIST OF CONTRACTS

 

	
No.
    	
 
    	
Description agreement
    	
 
    	
Date
    	
 
    	
Parties
    	
 
    	
Change of Control
   as result of Kairos
    	
 
    	
Remarks
    	
 
    	
Outstanding items
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
7.
    	
 
    	
An exclusive worldwide commercial (sub)license agreement with Xenon   Genetics Inc., under which AMT has obtained worldwide rights to use,   manufacture and commercialize intellectual property covering certain LPL   genes in the field of gene therapy to treat LPL deficiency and coronary   artery disease.
    	
 
    	
18-06-2001
    	
 
    	
OLD AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of the State of California
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
8.
    	
 
    	
Non-exclusive   worldwide commercial license agreement with Salk Institute for Biological   Studies, under which AMT has obtained rights to commercialize technology that   is a component for Glybera for LPLD.
    	
 
    	
08-02-2008
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of the State of California apply
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
9.
    	
 
    	
An exclusive worldwide commercial license agreement with a Sanofi   Aventis on, under which AMT has obtained rights in the major markets to use,   develop, manufacture and commercialize intellectual
    	
 
    	
20-12-2006
    	
 
    	
OLD AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of France apply
    	
 
    	
 
    

 

22

 

LIST OF CONTRACTS

 

	
No.
    	
 
    	
Description agreement
    	
 
    	
Date
    	
 
    	
Parties
    	
 
    	
Change of Control
   as result of Kairos
    	
 
    	
Remarks
    	
 
    	
Outstanding items
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
property covering a LPL gene in the field of gene therapy to treat LPL   deficiency. This agreement required AMT to pay an upfront signature fee and   requires AMT to pay both milestones and royalties to the licensor.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
10.
    	
 
    	
Non-exclusive   worldwide commercial license agreement with the National Institutes of Health   re – amongst others - production of AAV in insect cells and AAV 5 Vector.
    	
 
    	
02-05-2007 (as amended)
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of District of Colombia apply
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
11.
    	
 
    	
Development and commercialisation agreement Progenika
    	
 
    	
07-08-2009
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of England apply
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
12.
    	
 
    	
Non-exclusive   worldwide commercial sublicense agreement with Targeted Genetics Corporation,   under which AMT has obtained worldwide rights to commercialize the AAV1   capsid serotype used in Glybera® for LPLD.
    	
 
    	
05-12- 2006
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
Laws of Commonwealth of Pennsylvania apply
    	
 
    	
 
    

 

23

 

LIST OF CONTRACTS

 

	
No.
    	
 
    	
Description agreement
    	
 
    	
Date
    	
 
    	
Parties
    	
 
    	
Change of Control
   as result of Kairos
    	
 
    	
Remarks
    	
 
    	
Outstanding items
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
13.
    	
 
    	
License agreement with AMGEN re GDNF
    	
 
    	
30-11-2010
    	
 
    	
AMT B.V.
    	
 
    	
[No]
    	
 
    	
Laws of the State of New York apply
    	
 
    	
We have not been provided with the executed version.
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
14.
    	
 
    	
Development and manufacturing agreement with Institut Pasteur re   Sanfilippo
    	
 
    	
[07-01-2011]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Complete documentation to be submitted
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Grants
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
15.
    	
 
    	
Senternovem innovatiekrediet
    	
 
    	
18-12-2009
    	
 
    	
AMT N.V.
    	
 
    	
In the event of a transfer of knowhow or results originating from the   project, the Minister must be informed and he may decide that the credit must   be repaid immediately.

 

NB: Section 3.10 of the Subsidy Scheme Innovate (Subsidieregeling innoveren) states: that   in the event the shares in the grantee (AMT) are being sold, the Minister may   decide that (i)
    	
 
    	
The Senternovem innovatiekrediet must be transferred as it is in the   name of AMT N.V.
    	
 
    	
AMT N.V. had pledged the assets in relation to the Project (Duchenne).
    

 

24

 

LIST OF CONTRACTS

 

	
No.
    	
 
    	
Description agreement
    	
 
    	
Date
    	
 
    	
Parties
    	
 
    	
Change of Control
   as result of Kairos
    	
 
    	
Remarks
    	
 
    	
Outstanding items
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
the grant must be repaid at once or (i) the repayment is being   accelerated.
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
16.
    	
 
    	
Senter - TOK 000106 – LPL deficiency
    	
 
    	
27-06-2001
    	
 
    	
OLD AMT B.V.
    	
 
    	
AMT has committed not to transfer IP resulting from the project or   assets financed by the credit. Check clause 5 re Demerger.
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
17.
    	
 
    	
Senter – TOP – Il vivo gentherapy
    	
 
    	
12-03-2002
    	
 
    	
OLD AMT B.V.
    	
 
    	
AMT has committed not to transfer IP resulting from the project or   assets financed by the credit. Check clause 5 re Demerger.
    	
 
    	
 
    	
 
    	
OLD AMT B.V. has pledged the assets (Duchenne) in relation to the this   credit.
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
18.
    	
 
    	
Seventh framework programme – Treatrush (no. 242013)
    	
 
    	
01-02-2010
    	
 
    	
AMT [unclear which entity].

 

Agreements is signed by P. Morgan as CFO.
    	
 
    	
Section II.38 under (h) of Annex II to the grant agreement states that   the Commission may terminate the grant agreement where a legal, financial, 
    	
 
    	
The Agreement needs to be transferred if it is in the name of AMT N.V.

 

The change of control clause could be triggered in the event   AMT B.V. is contract party
    	
 
    	
It is unclear which AMT entity is party to the agreement. Assuming AMT   N.V. is the party to the agreement the agreement will need to be transferred.

 

Furthermore the grant 
    

 

25

 

LIST OF CONTRACTS

 

	
No.
    	
 
    	
Description agreement
    	
 
    	
Date
    	
 
    	
Parties
    	
 
    	
Change of Control
   as result of Kairos
    	
 
    	
Remarks
    	
 
    	
Outstanding items
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
organisational or technical change or change of control of a   beneficiary (AMT [N.V./B.V.]) calls into question the decision of the   Commission to accept its participation.
    	
 
    	
 
    	
 
    	
agreement needs to be reviewed.
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
19.
    	
 
    	
Proposal for grant agreement – AIP Digna grant (no. 261506)
    	
 
    	
[05]-07-2010
    	
 
    	
AMT B.V.
    	
 
    	
 
    	
 
    	
The documents we reviewed appear to be the proposal for a grant (under   the Seventh framework programme). The proposal does not contain a change of   control. However, depending on the applicable provisions (e.g. dee 18 above)   a change of control may be applicable.
    	
 
    	
Complete documentation to be submitted.
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Dilutive Instruments
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
20.
    	
 
    	
Convertible loan agreement Forbion
    	
 
    	
22-12-2009
    	
 
    	
AMT N.V.
    	
 
    	
No
    	
 
    	
The Agreement needs to be transferred as it is in the name of AMT N.V.
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Lease Agreements
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

26

 

LIST OF CONTRACTS

 

	
No.
    	
 
    	
Description agreement
    	
 
    	
Date
    	
 
    	
Parties
    	
 
    	
Change of Control
   as result of Kairos
    	
 
    	
Remarks
    	
 
    	
Outstanding items
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
21.
    	
 
    	
(Sub)Lease agreements with AMC and BDDA with OncoMethylome Sciences,   AMT and AVP relating to:
    	
 
    	
various
    	
 
    	
OLD AMT B.V.
    	
 
    	
No
    	
 
    	
Pursuant to annual accounts only the following leases exist:

 

Agreement between BDDA and AMT regarding leasehold improvements   “Meibergdreef 61” as from October 2005 for 11 years. The rent of the   leasehold improvements amounts to € 30,000 per year. The lease contract   contains an option to extend the lease for another 5 years. The company has   the right to cancel the lease earlier on a one-year term however, the company   will then need to repay the remaining amount of leased leasehold   improvements.

 

– Agreement between BDDA and AMT regarding leasehold improvements   “Meibergdreef 57” as from July 2006 for 10 years and 3 months. The rent of   the leasehold improvements amounts to € 23,000 per year. The lease
    	
 
    	
 
    

 

27

 

LIST OF CONTRACTS

 

	
No.
    	
 
    	
Description agreement
    	
 
    	
Date
    	
 
    	
Parties
    	
 
    	
Change of Control
   as result of Kairos
    	
 
    	
Remarks
    	
 
    	
Outstanding items
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
contract contains an option to extend the lease for another 5 years.
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
a
    	
 
    	
983 m2 on the second floor (1e etage) of   Meibergdreef 57
    	
 
    	
[11]-01-2007
    	
 
    	
Old AMT B.V.
    	
 
    	
No
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
c
    	
 
    	
968 m2 on the third floor (tweede etage)   between OncoMethylome Sciences B.V and BDDA and a sublease agreement re a   third of the 968 m2 on the third floor (tweede etage)   between OncoMethylome Sciences B.V and AMT B.V.
    	
 
    	
31-12-2006

 

 

[15-02-2007]
    	
 
    	
 

 

 

Old AMT B.V
    	
 
    	
No
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
b
    	
 
    	
an amendment to the sublease agreement with OncoMethylome Sciences
    	
 
    	
[09-05-2007
    	
 
    	
Old AMT B.V
    	
 
    	
No
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
e
    	
 
    	
(termination of) old (first and second) rental agreements
    	
 
    	
16-06-2007
    	
 
    	
Old AMT B.V
    	
 
    	
No
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
f
    	
 
    	
605 m2 on the fourth floor (derde etage)   (Meibergdreef 61).
    	
 
    	
13-10-2007
    	
 
    	
OLD AMT B.V.
    	
 
    	
No
    	
 
    	
 
    	
 
    	
 
    

 

28

 

LIST OF CONTRACTS

 

	
No.
    	
 
    	
Description agreement
    	
 
    	
Date
    	
 
    	
Parties
    	
 
    	
Change of Control
   as result of Kairos
    	
 
    	
Remarks
    	
 
    	
Outstanding items
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
g
    	
 
    	
256m2 on the fifth floor (vierde etage)   between AVP and BDDA
    	
 
    	
01-10-2005
    	
 
    	
AVP
    	
 
    	
No
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
h
    	
 
    	
A GMP facility on Meibergdreef 61 between AVP and BDDA
    	
 
    	
01-07-2001
    	
 
    	
AVP
    	
 
    	
No
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Pension / Insurance
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
22.
    	
 
    	
Pension
    	
 
    	
[-]-07-2008 / 07-04-2010
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
23.
    	
 
    	
D&O Insurance
    	
 
    	
[06-06-2010]
    	
 
    	
AMT N.V.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
The most up to date schedule to the insurance agreement to be   reviewed.
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Other
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
24.
    	
 
    	
Named patients supply agreement with Pioneer Market Acces Consulting   (as amended)
    	
 
    	
05-05-2010
    	
 
    	
AMT B.V.
    	
 
    	
No
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
25.
    	
 
    	
Employment agreement Mr. Jörn Aldag
    	
 
    	
[·]-10-2009
    	
 
    	
AMT N.V.
    	
 
    	
Pursuant to section 1.4 of the Agreement, in the event of (a) new   controlling shareholder(s) of AMT N.V. decide not to maintain Mr. Aldag as   CEO (or a position
    	
 
    	
 
    	
 
    	
 
    

 

29

 

LIST OF CONTRACTS

 

	
No.
    	
 
    	
Description agreement
    	
 
    	
Date
    	
 
    	
Parties
    	
 
    	
Change of Control
   as result of Kairos
    	
 
    	
Remarks
    	
 
    	
Outstanding items
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
at least equivalent) then Mr. Aldag has the right to terminate the   agreement within two months.
    	
 
    	
 
    	
 
    	
 
    

 

30

 

SCHEDULE 4 — PURCHASER WARRANTIES

 

1.                                     The Purchaser is duly organised and validly existing as a besloten vennootschap met beperkte aansprakelijkheid under the laws of the Netherlands and the Purchaser has all requisite power to enter into the Agreement.

 

2.                                     The Purchaser is duly registered with the trade register held by the competent Chamber of Commerce.

 

3.                                     The Purchaser has not been dissolved and no resolution to dissolve the Purchaser has been adopted.

 

4.                                     The Purchaser has not requested nor been granted a moratorium of payment and the Purchaser has not been declared bankrupt and to its best knowledge no action or request is pending to declare the Purchaser bankrupt.

 

5.                                     This Agreement has been duly authorised by the Purchaser and will constitute valid and legally binding obligations of the Purchaser enforceable against the Purchaser in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganisation or other similar laws affecting the enforcement of the creditors’ rights generally or by general principles of equity.

 

6.                                     The (class A) ordinary shares in the capital of the Purchaser shall be validly issued and placed, fully paid up and free and clear of Encumbrances. The uniQure DRs and the (class B) ordinary shares in the capital of the Purchaser underlying the uniQure DRs shall be validly issued and placed, fully paid up and free and clear of Encumbrances.

 

1

 

SCHEDULE 5 — SELLER WARRANTIES

 

1.                                     Each of the Subsidiaries is duly organised and validly existing as a besloten vennootschap met beperkte aansprakelijkheid under the laws of the Netherlands, each of the Subsidiaries has the corporate power to carry on its business as presently conducted and each of the Subsidiaries has all requisite power to enter into the Agreement.

 

2.                                     Each of the Subsidiaries is duly registered with the trade register held by the competent Chamber of Commerce.

 

3.                                     Neither of the Subsidiaries has been dissolved and no resolution to dissolve either of the Subsidiaries has been adopted.

 

4.                                     Neither of the Subsidiaries has requested or been granted a moratorium of payment and neither of the Subsidiaries has been declared bankrupt and to the Seller’s best knowledge no action or request is pending to declare either of the Subsidiaries bankrupt.

 

5.                                     The Sale Shares have been validly issued and placed. The Sale Shares are free and clear of Encumbrances. There are no depositary receipts (certificaten van aandelen) of the Sale Shares in existence. The Seller is the sole and exclusive legal and beneficial owner of the Sale Shares.

 

6.                                     The Seller has not granted any rights to acquire shares in the capital of the Subsidiaries through subscription, conversion or otherwise.

 

7.                                     The Seller has no actual or contingent obligation to transfer any of the Sale Shares to a third party (with the exception of the obligations of Seller to Purchaser arising out of this Agreement), or to create any Encumbrance in respect of the Sale Shares.

 

8.                                     The Seller has full right, power and authority to sell and transfer the Sale Shares.

 

9.                                     The Seller is duly organised and validly existing as a naamloze vennootschap under the laws of the Netherlands and has all requisite power to enter into this Agreement.

 

10.                              This Agreement has been duly authorised by the Seller and each of the Subsidiaries and on the Completion Date will constitute valid and legally binding obligations of the Seller and each of the Subsidiaries enforceable against them in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganisation or other similar laws affecting the enforcement of the creditors’ rights generally or by general principles of equity.

 

2

 

SCHEDULE 6 — PROJECT KAIROS TERM SHEET

 

3

 

 

STRICTLY CONFIDENTIAL

 

TERM SHEET

PROJECT UNIQURE

 

This term sheet (the Term Sheet) summarizes the principal proposed terms of the cooperation among (i) Forbion Co-Investment II Coöperatief U.A., Coöperatieve AAC LS U.A. and Forbion Co-Investment Coöperatief U.A. (together referred to as Forbion) and (ii) uniQure B.V. (uniQure, or the Company) as the company.

 

uniQure intends to acquire the assets and liabilities of Amsterdam Molecular Therapeutics (AMT) Holding N.V. (AMT together with Forbion and uniQure: the Parties, or each: a Party), in exchange for depositary receipts (each: a DR and any holder of a DR: a DR Holder) for ordinary shares issued by a foundation (stichting administratiekantoor) holding ordinary shares in the capital of uniQure (STAK) (the AMT Transaction) pursuant to a business acquisition agreement (the BAA), to be entered into between, inter alia, uniQure and AMT. Upon completion of the AMT Transaction (the BAA Completion), AMT will be dissolved and the DRs will be distributed to the AMT shareholders, whereupon holders of shares representing 5% or more of the issued and outstanding share capital of AMT immediately following BAA Completion (together with Forbion: the Investors, or each: an Investor) will be offered to exchange their DRs for shares in the capital of uniQure (the Exchange Offer).

 

Now, the Parties agree that (i) a shareholders’ agreement in respect of uniQure, as well as (ii) ancillary documentation such as (a) the articles of association (statuten) of uniQure, (b) articles of incorporation of STAK, (c) the terms and conditions (administratievoorwaarden) of STAK, and (d) related documentation (all together, the Governing Documents) shall be entered into or, as the case may be, come into full force and effect immediately prior to BAA Completion. Upon BAA Completion, also completion under the Governing Documents (Completion) shall occur. The Parties agree that the documentation referred to above shall reflect the terms and conditions of this Term Sheet and shall furthermore be negotiated in good faith prior to Completion.

 

The proposed subject matter of this Term Sheet is specifically subject to the conditions set forth herein.

 

1              CHRONOS TRANSACTION

 

1.1                              General principles

 

·                                          uniQure and AMT N.V. (AMT) negotiate the BAA for the acquisition by uniQure of the assets and liabilities of AMT.

 

·                                          AMT must convocate a general meeting of shareholders in order to obtain shareholder approval for the AMT Transaction. The timing of the shareholders meeting is 42 days after the convocation. Together with the convocation, the BAA and a summary thereof and of the other terms of the AMT Transaction will be circulated to the AMT shareholders in a shareholders circular (the Shareholders Circular). The Shareholders Circular shall be prepared by AMT and uniQure jointly.

 

 

·                                          In consideration of the assets and liabilities to be acquired by uniQure, uniQure shall issue a number of DRs, equal to the aggregate number of shares in the capital of AMT issued and outstanding at the time of the BAA Completion.

 

·                                          Forbion shall convert its convertible loan (with a face value of EUR 5,000,000) together with accrued interest immediately after BAA Completion at an agreed (and revised) conversion price of EUR 1 per share.

 

·                                          uniQure shall procure that the DRs so distributed to AMT will be accepted for clearing and trading through the clearing systems of Euroclear Nederland. The DRs shall be distributed to the AMT shareholders upon the shareholders meeting of AMT having resolved to liquidate AMT. Pursuant to the Governing Documents, the shares held by STAK will be subject to a drag right by the requisite number of Investors.

 

·                                          The distribution to AMT shareholders shall not be deemed an ‘offer of securities’ under the terms of the Financial Supervision Act (Wft) and consequently in respect of such distribution AMT (or uniQure) will not be required to offer a prospectus).

 

·                                         uniQure will offer each holder of DRs representing 5% or more of the issued and outstanding share capital of AMT immediately following BAA Completion to exchange its DRs in ordinary shares in the capital of uniQure (the Exchange Offer). As the Exchange Offer will be made to less than 100 persons, uniQure is exempted from issuing a prospectus in respect of the Exchange Offer.

 

·                                          AMT’ shareholders meeting shall resolve to dissolve AMT, with the DRs to be distributed in the context of such dissolution.

 

1.2                              Business purchase agreement and conditions precedent

 

The BAA shall be subject to, inter alia, the following conditions precedent:

 

(i)             the approval of AMT’ shareholders meeting of the AMT Transaction; and

 

(ii)                                 an irrevocable equity funding of at least EUR 1 million by a new investor (the New Investor), at terms acceptable to uniQure; and

 

(iii)                              no material adverse change will occur in the profitability, financial or trading position or the prospects of AMT and/or any of its subsidiaries; and

 

(iv)                             Senter Novem has agreed with a transfer of all existing contracts with AMT to uniQure.

 

1.3                              Public announcements

 

Regulatory rules require AMT to make public announcements through a press release, inter alia, immediately upon occurrence of the following events:

 

·                                          shareholders approval of the AMT Transaction;

 

·                                          execution of the BAA; and

 

2

 

 

·                                          BAA Completion.

 

2                                         UNIQURE

 

(A)                               Corporate structure, Capitalization and new Funding

 

	
No.
    	
 
    	
Subject
    	
 
    	
Term
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(1)
    	
 
    	
Company
    	
 
    	
uniQure B.V., a newly   incorporated Dutch private limited liability company (besloten vennootschap met beperkte   aansprakelijkheid).
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(2)
    	
 
    	
Capitalization (authorized   capital)
    	
 
    	
Different classes of ordinary shares (with a nominal   value of EUR 0.01 each) (Ordinary Shares),   to allow each Investor to hold Ordinary Shares of a separate class, with   Investors holding Ordinary Shares Class A and STAK holding Ordinary Shares   Class B.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(3)
    	
 
    	
New Financing
    	
 
    	
Forbion to commit to an investment in an amount of   EUR 6 million and New Investor to commit to an irrevocable equity funding in an amount   of at least EUR 1 million, to be effected by issuing Ordinary Shares Class A at a price   per Ordinary Share of EUR 0.614 eac h (the New   Investment).
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(4)
    	
 
    	
Anti-dilution   Protection
    	
 
    	
Ordinary Shares Class   A issued to Forbion and the New Investor pursuant to the New Investment will   be entitled to full ratchet anti-dilution rights in subsequent rounds where   the per share consideration received by the Company is less than the per   share consideration paid by Forbion and the New Investor pursuant to the New   Investment. These anti-dilution rights shall be subject to carve-outs for   shares issued to employees, consultants and directors. In such case, new   shares in the Company are to be issued either with payment to be made from   the Compnay’s share premium reserve, or if not available, such new shares are   to be issued at par value and transferred to Forbion and the New Investor,   with the number of shares computed according the following formula:

 

(P1-P2) / P2) x Q

 

Whereas:

 

(i)                                     P1 to mean the issue price paid by Forbion and the New Investor pursuant   to the New Investment;

 

(ii)                                  P2 to mean the issue price offered in the subsequent capital increase.
    

 

3

 

	
 
    	
 
    	
 
    	
 
    	
Q to mean the number of shares subscribed by Forbion and the New Investor   pursuant to the New Investment.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(5)
    	
 
    	
Capitalization   (issued capital)
    	
 
    	
Upon BAA Completion   (post conversion of the Forbion convertible loan, as set out above), full   acceptance of the Exchange Offer and completion of the New Investment, the   issued capital of uniQure shall be held as set out in Schedule 3.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(6)
    	
 
    	
STAK
    	
 
    	
Stichting   Administratiekantoor, holder of the Ordinary Shares Class B and issuer of DRs (without the   Company’s cooperation) (certificaten)   to certain eligible investors in AMT (the DR Holders), entitling the DR   Holders to the distribution of the profits of uniQure relating to the   Ordinary Shares held by STAK, for each DR Holder in proportion to the number   of DRs that they hold. DR Holders shall be entitled to instruct the STAK   management board how to vote on the shares underlying the DRs they hold in a   general meeting of shareholders of uniQure. The STAK management board shall   vote shares for which no instruction has been given by the DR holder entitled   thereto.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(7)
    	
 
    	
STAK   management board
    	
 
    	
2 DR representatives   and 1 independent member.
    

 

(B)                               Governance

 

	
No.
    	
 
    	
Subject
    	
 
    	
Term
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(8)
    	
 
    	
Management board
    	
 
    	
The management board of uniQure (the MB) shall initially consist of the   directors currently constituting the AMT’ management board, i.e. Mr. J. Aldag   and Mr. P.J. Morgan (employment conditions subject to review by Forbion). Any   AMT stock option plan currently in force and applicable to Mr. J. Aldag and   Mr. P.J. Morgan will terminate on BAA Completion and will be replaced by a   new uniQure stock option plan. Prior to BAA completion, Mr. J. Aldag and Mr. P.J.   Morgan will be required to waive any rights they may be entitled to under any   current existing AMT stock option plan.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(9)
    	
 
    	
Supervisory   board
    	
 
    	
The supervisory board of uniQure (the SB) shall initially consist of 3 investor   representatives (the Investor   Representatives) and 4 other members, i.e. S.J.H. van Deventer,   H.A. Slootweg and a person nominated in accordance with Schelude 1, as the Investor Representatives, and J.M. Feczko, P.M.M.J.   van Holle, F. Meyer and a newly to be appointed independent member, as the   independent members.
    

 

4

 

	
(10)
    	
 
    	
Supervisory   board committees
    	
 
    	
The SB shall have at least two standing committees, i.e. the audit   committee and the remuneration and appointment committee, to be appointed by   the SB from its own members. Each committee shall consist of 3 members, of   which 1 Investor Representative.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(11)
    	
 
    	
Governance   (Management Board and Supervisory Board)
    	
 
    	
Schedule 1 sets out   specific governance provisions in relation to uniQure relating to Management   Board and Supervisory Board resolutions.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(12)
    	
 
    	
Governance (General Meeting)
    	
 
    	
Schedule 2 sets out   specific governance provisions in relation to uniQure relating to resolutions   of the General Meeting.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(13)
    	
 
    	
ESOP
    	
 
    	
To provide further   incentives to employees, directors and or outside consultants and advisors,   contemporary with completion of the AMT Transaction, the shareholders of the   Company will authorise a new unallocated pool of options and / or warrants   for future grants to employees, directors and / or outside consultants and   advisors, representing 15% of the fully diluted share capital of the Company   post BAA Completion, with (i) a vesting period of three years; 1/3 of the options to be vested   after one year, the other 2/3 to be vested in year 2 and 3 on a pro rata —   i.e. linear — basis; and (ii) the exercise price of the options being the   price paid by Forbion. The SB shall be authorised to grant options or   warrants within the scheme. A resolution of the SB to this effect requires   the positive vote of at least two Investor Representatives.
    

 

(C)                               Transfers of Shares

 

	
No.
    	
 
    	
Subject
    	
 
    	
Term
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(14)
    	
 
    	
Transfer of Ordinary Shares
    	
 
    	
Each transfer of Ordinary Shares (be it to an   Investor’s affiliate or group company, a Portfolio Transfer, a Sale or   otherwise) is always subject to the condition that the purchaser of such   transferred Ordinary Shares is or becomes bound to the Governing Documents.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(15)
    	
 
    	
Transfers of DRs
    	
 
    	
DRs are freely transferable, subject to restrictions   under applicable laws.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(16)
    	
 
    	
Portfolio   Transfer
    	
 
    	
Subject to the requirement for a transferee to sign   a deed of adherence, the Ordinary Shares shall at all times be freely   transferable (other than to competitors of the Group) as part of a transfer   of an Investor’s investment portfolio (in whole or in part) or to entities in   which an Investor has an economic interest (Portfolio   Transfer).
    

 

5

 

	
(17)
    	
 
    	
Right   of first offer other Investors
    	
 
    	
If an Investor intends to sell (the Selling Investor) any Ordinary Shares   other than in a Portfolio Transfer, or transfers to affiliates, the following   shall apply. The Selling Investor shall notify the other Investors of its   wish to sell Ordinary Shares and shall invite the other Investors to make an   offer, on the basis of a minimum price, for these Ordinary Shares within 2   weeks from receipt of the notice. The Ordinary Shares offered shall be   allocated to the other Investors that have made an offer for at least the   minimum price for the price offered by the relevant Investors. If the other   Investors have not subscribed for all Ordinary Shares offered for sale by the   Selling Investor, the Selling Investor is free to offer those shares to any   third party for a price at least equal to the minimum price stated in the   notice to the other Investors.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(18)
    	
 
    	
Good   and Bad Leaver
    	
 
    	
Equity interests to be granted to employees,   directors and / or outside consultants and advisors pursuant to the employee   stock option plan shall be made subject to good- and bad leaver arrangements   pursuant whereto the relevant person will be required to offer their   interests to (a person designated by) the Company in case such person’s   employment (or other) contract with the Company (or a group company of the   Company) terminates.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(19)
    	
 
    	
Tag   offer
    	
 
    	
If Investors holding 51% or more of the issued and   outstanding Ordinary Shares Class A propose to sell Ordinary Shares to a   third party (a Sale), each other   holder of Ordinary Shares will have the right (as a condition to such Sale)   to require that third party purchaser to purchase a pro rata portion of such   holder’s Ordinary Shares (a Tag Offer)   to be completed simultaneously with the Sale.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(20)
    	
 
    	
Drag   offer
    	
 
    	
In case of a Sale, the proposed seller or sellers   may, upon agreement of the terms and conditions of a bona fide offer by a   third party purchaser for one or more of its or their Ordinary Shares (a Drag Offer) require each (other) holder   of Ordinary Shares to transfer all (but not less than all) of such shares   (the Drag Shares) on the same   terms and conditions as those offered in the Drag.
    

 

(D)                               Exit

 

	
No.
    	
 
    	
Subject
    	
 
    	
Term
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(21)
    	
 
    	
Intention to Exit
    	
 
    	
It is the intention of the Investors, that an Asset   Sale or an Exit be achieved as soon as practically possible and commercially   sensible.
    

 

6

 

	
(22)
    	
 
    	
Nature of an Exit
    	
 
    	
An Exit   shall be:

 

·                  a transfer (or a series of   related transfers) of all the Ordinary Shares issued (other than as a result   of a transfer by an Investor to an affiliate);

 

·                  the listing and admission to   trading on a market for listed securities of either (i) the Company’s shares,   (ii) an intermediate holding company’s shares or (iii) the shares of new   holding company established for the purposes of the Listing (a Listing); or

 

·                  a distribution pursuant to a   winding-up or dissolution of the Company or any holding company of the   Company, including following an Asset Sale.

 

An Asset Sale   shall be a sale by one or more Group Companies of all, or substantially all,   of the Group’s business, assets and undertaking.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(23)
    	
 
    	
Appointment   of Advisors
    	
 
    	
Investors holding 51% or more of the issued and outstanding Ordinary Shares Class A and the Company shall   jointly decide on the appointment by the Company of its advisors in   connection with the Exit.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(24)
    	
 
    	
Obligations   on an Exit or an Asset Sale
    	
 
    	
The Company shall co-operate and take such steps as   reasonably required (taking into account their rights and obligations under   this term sheet) in respect of any proposed Exit or Asset Sale subject always   to fiduciary duties and compliance with applicable law.
    

 

(E)                                Miscellaneous

 

	
No.
    	
 
    	
Subject
    	
 
    	
Term
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(25)
    	
 
    	
Provision of Information
    	
 
    	
The Company shall be required to supply to the   Investors:

 

·                  at least 30 business days prior to the start of the new financial year, a   draft annual budget (for comment) including profit and loss projections,   monthly cash flow projections and balance sheet projections including line   items on total proposed (i) capital expenditure, (ii) project financing and   (iii) total costs of other investments for comments by the Investors;

 

·                  within 30 days after the start of the relevant financial year, the annual   budget per the above specifications;

 

·                  within 15 business days after the end of each month, a monthly   information package to include (i) updated
    

 

7

 

	
 
    	
 
    	
 
    	
 
    	
liquidity forecast (12 months, in aggregate and   breakdown per major project) and reconciliation with previous month, (ii) qualitative   comments highlighting development progress, financing events and sales   process, and (iii) progress reporting on 5 biggest projects (format to be   acceptable to Investors holding 51% or more of the issued and outstanding   Ordinary Shares Class A, but in any case shall include executive summary on   key elements (progress, costs, liquidity against budget etc));
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
·                  within 20 business days after the end of each quarter, a quarterly   information package to include (i) monthly information, (ii) updated format   revised business plan; (iii) a reconciliation with previous quarterly revised   business plan; (iv) progress reporting on 5 biggest projects (format to be   acceptable to Investors holding 51% or more of the issued and outstanding   Ordinary Shares Class A (acting reasonably) but in any case shall include:   (a) executive summary on key elements (progress, costs, liquidity against   budget, project financing, general economical climate etc) and (b) project   monitor summary if project has commenced (to be delivered in the same format   as required by the financiers of the relevant project, if available) and (v) reporting   on financing (format to be acceptable to Investors holding 51% or more of the   issued and outstanding Ordinary Shares Class A (acting reasonably) but shall   in any case include regularity of all financings);
    
	
 
    	
 
    	
 
    	
 
    	
·                  as soon as they become available, copies of annual valuations of   underlying assets; and
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
·                  other information reasonably required by Investors holding 51% or more of   the issued and outstanding Ordinary Shares Class A.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
The format of the reporting shall be designed by the   Company and shall be in form and substance satisfactory to Investors holding   51% or more of the issued and outstanding Ordinary Shares Class A.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(26)
    	
 
    	
STAK Information Rights
    	
 
    	
·                  Within 20 business days   after a general meeting of shareholders of the Company, the DR Holders shall   be entitled to receive from the STAK management board a copy of the adopted   annual accounts and a list of resolutions adopted by the general meeting of shareholders.

 

·                  Within 20 business days   after the end of each quarter, the DR Holders shall be entitled to receive   from the STAK management board a quarterly financial statement, in a format
    

 

8

 

	
 
    	
 
    	
 
    	
 
    	
to be approved by the SB.

 

·                  There shall be no obligation   to make the information as referred to in this section 0 publicly available   by placing it on the Company’s or any other website.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(27)
    	
 
    	
Compensation of costs
    	
 
    	
The Company and / or   AMT shall bear the costs reasonably incurred (including, for the avoidance of   doubt, legal fees) by Forbion in connection with the AMT Transaction in the   event that (i) BAA Completion occurs or (ii) the BAA is terminated as a   result whereof and pursuant to the BAA, the Company will be paid a break fee.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(28)
    	
 
    	
Confidentiality
    	
 
    	
Investors will be subject to customary restrictions   on the use and disclosure of confidential information.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(29)
    	
 
    	
Accounting   regime
    	
 
    	
Dutch GAAP will apply. The audit committee will be   authorised to adopt IFRS as the applicable accounting standard.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
(30)
    	
 
    	
Governing   law
    	
 
    	
This term sheet is governed by Dutch law. The   definitive documents will be governed by Dutch law.
    

 

[signature page to follow]

 

9

 

	
Signed and agreed on
    	
16-2-2012
    	
.
    

 

 

	
/s/ H.A. Slootweg
    	
 
    	
/s/ M.A. van Osch
    
	
uniQure B.V.
    	
 
    	
uniQure B.V.
    
	
By: 
    	
Forbion 1 Co II   Management B.V.
    	
 
    	
By: 
    	
Forbion 1 Co II   Management BV
    
	
By: 
    	
H.A. Slootweg  

Director
    	
 
    	
By: 
    	
M.A. van Osch  

director
    
	
Date: 
    	
16-2-2012
    	
 
    	
Date: 
    	
16-2-12
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
/s/ H.A. Slootweg
    	
 
    	
/s/ M.A. Jan Osch
    
	
Forbion Co-Investment II Coöperatief U.A.
    	
 
    	
Forbion Co-Investment II Coöperatief U.A.
    
	
By: 
    	
Forbion 1 Co II   Management B.V.
    	
 
    	
By: 
    	
M.A. van Osch
    
	
By: 
    	
H.A. Slootweg
    	
 
    	
 
    	
director
    
	
 
    	
Director
    	
 
    	
Date: 
    	
16-2-2012
    
	
Date: 
    	
16-2-2012
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
/s/ H.A. Slootweg
    	
 
    	
/s/ M.A. van Osch
    
	
Cooperatieve AAC LS U.A.
    	
 
    	
Cooperatieve AAC LS U.A.
    
	
By: 
    	
Forbion 1 Management   B.V.
    	
 
    	
By: 
    	
Forbion 1 Management   BV
    
	
By: 
    	
H.A. Slootweg
    	
 
    	
By: 
    	
M.A. van Osch
    
	
 
    	
Director
    	
 
    	
 
    	
director
    
	
Date: 
    	
16-2-2012
    	
 
    	
Date: 
    	
16-2-2012
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
/s/ H.A. Slootweg
    	
 
    	
/s/ M.A. van Osch
    
	
Forbion Co-Investment II Coöperatief U.A.
    	
 
    	
Forbion Co-Investment II Coöperatief U.A.
    
	
By: 
    	
Forbion 1 Management   B.V.
    	
 
    	
By: 
    	
Forbion 1 Management   BV
    
	
By: 
    	
H.A. Slootweg
    	
 
    	
By: 
    	
M.A. van Osch
    
	
 
    	
Director
    	
 
    	
 
    	
director
    
	
Date: 
    	
16-2-2012
    	
 
    	
Date: 
    	
16-2-2012
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Amsterdam Molecular Therapeutics (AMT) Holding N.V.
    	
 
    	
Amsterdam Molecular   Therapeutics (AMT) Holding N.V.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
/s/ Jörn Aldag
    	
 
    	
By:
    	
/s/ PJ Morgan
    
	
 
    	
 
    	
 
    	
 
    	
PJ Morgan
    
	
Date:
    	
16.02.2012
    	
 
    	
Date:
    	
CFO
    

 

10

 

SCHEDULE 1: GOVERNANCE (MANAGEMENT BOARD AND SUPERVISORY BOARD)

 

This schedule and the allocation in respect of reserved matters assumes the following starting points:

 

1.                          The Company shall have a Management Board and a Supervisory Board.

 

2.                          The Management Board shall consist of 2 or more members appointed by the general meeting of shareholders of the Company (the General Meeting) in accordance with a binding nomination by any Investor or group of Investors holding at least 51% of the Ordinary Shares Class A.

 

3.                          The Supervisory Board shall consist of 7 directors, of whom 3 directors (one of whom shall be the chairman of the Supervisory Board (the Chairman)) shall be appointed by the General Meeting in accordance with a binding nomination by any Investor or group of Investors holding at least 51% of the Ordinary Shares Class A. Prior to the making of a nomination the Investors shall consult with the other Investors and STAK about the identity and the qualifications of such person included on a shortlist of potential nominees and the Investors shall take any substantiated objections against potential nominees into account in making their decision to formally nominate such person. In case of a deadlock of votes in a meeting of the Supervisory Board, the Chairman will have a casting vote.

 

4.                          The Supervisory Board shall meet at least 6 times per year (or such other number as the Chairman may require) in person at scheduled meetings and so often as required for the proper fulfilment of the role of the Supervisory Board, either in person or by conference call.

 

5.                          The Management Board will be responsible for all operational matters in respect of the Company and its subsidiaries (collectively: the Group and any member of the Group also: a Group Company) but will require the prior approval of the Supervisory Board acting by simple majority for the matters listed in Part A of this Schedule.

 

6.                          The items listed in Parts B and C of this Schedule will require approval by or the adoption of a prior resolution of Investors holding at least 51% or 662/3%, respectively, of Class A Ordinary Shares held by Investors.

 

Part A

 

Supervisory Board approval

 

(a)                                 Any amendment of articles of association of any Group Company.

 

(b)                                 Voting on shares or similar equity interests in a Group Company (which provision would need to be mirrored in articles of association of Group Companies), for resolutions mentioned in Part A, B and C.

 

(c)                                  The instigation or the settlement of any material litigation or arbitration or mediation proceedings by a Group Company, for the purpose of which ‘material’ shall mean an interest or claim that is of strategic importance to the Group or has a monetary value of at least EUR 100,000.

 

11

 

(d)                                 Any proposals to the General Meeting to materially change the emoluments of members of the Management Board, including bonuses and option schemes.

 

(e)                                  The removal or appointment of the auditors of any Group Company, other than the reappointment of existing auditors.

 

(f)                                   Remuneration of the auditors of the Company.

 

(g)                                  Approval of any change in accounting policies of any Group Company.

 

(h)                                Alteration to the financial year end of any Group Company.

 

(i)                                     Non-project related capital expenditure exceeding in one transaction or event or a series of related transactions or events, in excess of an amount of EUR 50,000 but less than EUR 100,000, which is not included in an approved business plan or budget.

 

Part B

 

Approval with Simple Majority Investor Consent (51%) of Class A Ordinary Shares held by Investors

 

(a)                                Unless specified in an approved business plan of the Company, entering into or materially changing borrowing and lending arrangements (including issuance of debt instruments) by any Group Company, exceeding an amount of EUR 250,000.

 

(b)                                Unless specified in an approved business plan of the Company, establishing/closing any material branch, establishment, agency or business of any Group Company.

 

(c)                                 Unless specified in an approved business plan of the Company, entering into any material joint venture, partnership or profit sharing arrangement or licensing agreement by any Group Company.

 

(d)                                Unless specified in an approved business plan of the Company, the expansion or development of the Group or any of its business other than through a Group Company.

 

(e)                                 Adoption of or amendment to the current business plan (to be in agreed form) and budget (to be in agreed form).

 

(f)                                  Creation or release of any security or (save in the ordinary course of trading and consistent with past practice) granting of guarantees by any Group Company, exceeding an amount of EUR 250,000.

 

(g)                                 Unless specified in an approved business plan of the Company, any material acquisitions or disposals by any Group Company.

 

(h)                                The appointment or removal of any member of the Supervisory Board or Managing Director of a Group Company other than the Company.

 

12

 

(i)                                    Non-project related capital expenditure exceeding in one transaction or event or a series of related transactions or events, in an amount of EUR 100,000 or more, which is not included in an approved business plan or budget.

 

(j)                                   Establishment and material amendment of any management incentive scheme of any Group Company (other than the Company).

 

Part C

 

Approval with Qualified Majority Investor Consent (66 2/3%) of Class A Ordinary Shares held by Investors

 

(a)                                Any change in a Group Company’s (other than the Company’s) share capital.

 

(b)                                Unless specified in an approved business plan of the Company, any material change of the nature or the name of the business of the Group.

 

(c)                                 Entry into, termination or variation of any contract or arrangement by a Group Company with an Investor, other than financing arrangements.

 

(d)                                Any distribution from reserves (other than wholly intra-group) by any Group Company.

 

(e)                                 Transactions by a Group Company outside of its ordinary course.

 

(f)                                  Taking steps to commence insolvency or winding-up proceedings of a Group Company (including the application for suspension of payment of debts by a Group Company).

 

13

 

SCHEDULE 2: GOVERNANCE (SHAREHOLDERS MEETING)

 

Part A

 

Approval with Qualified Shareholder Consent

 

The following resolutions of the General Meeting will require the affirmative vote of Shareholders holding at least 662/3% of Ordinary Shares.

 

Approval with Qualified Majority Shareholder Consent (66 2/3%) of Ordinary Shares

 

a)                                     The merger (fusie) or demerger (splitsing) of the Company.

 

b)                                     The initiation of liquidation or dissolution of the Company or approve the filing for bankruptcy.

 

c)                                      The amendment of the articles of association of the Company.

 

d)                                     Appointment or dismissal of the Company’s auditors.

 

Part B

 

Approval with Simple Majority Investor Consent (51%) of Class A Ordinary Shares held by Investors

 

The following resolutions of the General Meeting will require the affirmative vote of Investors holding at least 51% of Class A Ordinary Shares.

 

a)                                     The issue of new equity securities (including options and warrants).

 

b)                                     The exclusion or restriction of pre-emptive rights with respect to the issue of new equity securities.

 

c)                                      The redemption (intrekking) or the reduction of the nominal value of any shares.

 

d)                                     The purchase (inkoop) by the Company of shares in its own capital, shares in the capital of any subsidiary, or depositary receipts (certificaten van aandelen) representing any such shares (whether or not issued “with the co-operation of the Company”).

 

e)                                      The declaration of dividends or distributions.

 

f)                                       The delegation of powers with respect to the issue of securities, the exclusion of pre-emptive rights, or the approval of the purchase of the Company’s own shares.

 

g)                                      Determination or variation of the remuneration of members of the Management Board and of the Supervisory Board.

 

14

 

·                  SCHEDULE 3: ISSUED CAPITAL IMMEDIATELY UPON FULL ACCEPTANCE OF THE EXCHANGE OFFER

 

15

 

SCHEDULE 7 – PRESS RELEASE 

 

4

 

 

Not for release, publication or distribution in whole or in part, directly or indirectly, in or into the United States or to US persons.  This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States or any other jurisdiction.

 

Amsterdam Molecular Therapeutics Business to be Acquired by uniQure BV

 

Extraordinary Shareholder Meeting called to vote on the Transaction

 

Amsterdam, The Netherlands — February 17, 2012 — Amsterdam Molecular Therapeutics (Euronext:  AMT) announced today that its board of directors is recommending a substantial corporate restructuring and financing transaction which, if approved by shareholders, will result in the assets and certain liabilities being acquired by a newly formed private company, uniQure BV, and the AMT legal entity being liquidated and delisted.

 

This transaction will:

 

·                                          support the future funding of AMT’s current gene therapy development pipeline;

·                                          reduce operating costs; and

·                                          enable disposal of current loan note obligations.

 

Consequently, management believes the uniQure transaction will allow AMT’s shareholders to benefit from the future potential value in the business.  This includes, if successful, completion of the ongoing collaboration discussions for the hemophilia B program and further collaborations on the GDNF program.

 

AMT has entered into a definitive agreement with Amsterdam-based uniQure to acquire the assets and certain liabilities of AMT in return for unlisted uniQure depository receipts (“DRs”) which may be exchangeable for uniQure shares as described further below.  There is no cash component to the consideration.  The proposed transaction has been evaluated by a special committee of the board (“Special Committee”) together with Ernst & Young, which has advised the Special Committee that the Transaction is fair and reasonable so far as AMT shareholders are concerned.  The disposal of the company’s programs, assets and certain liabilities has been unanimously approved by the board of supervisory directors, which recommends that AMT shareholders adopt the resolution at an Extraordinary Shareholder Meeting on March 30, 2012.

 

 

On completion, uniQuire will receive additional equity funding of € 7.0 million, including € 6.0 million from Forbion Capital managed funds together with € 1.0 million in additional new financing to be secured by AMT prior to completion.  In addition, uniQure will take over AMT’s liability related to the € 5.0 million convertible loan notes and accrued interest of € 0.3 million.  AMT will receive one new uniQure DR for every existing issued and outstanding AMT share.  AMT will subsequently be dissolved and, as an advance liquidation payment, the uniQure DRs shall be distributed to AMT’s shareholders.  The uniQure DRs shall not be listed.

 

“We believe the proposed transaction will ensure the future of AMT following the failure to gain approval of Glybera in 2011 given the very limited options available to us.  While we have pursued various avenues to raise additional funds on the open capital markets, worked diligently to engage in partnering discussions and have cut personnel, programs and spending down drastically, we are ultimately still facing a very precarious financial position with a cash reach to early April,” explained Jörn Aldag, CEO of AMT.  “The Transaction offers the only viable way to secure a capital injection, the ability to better focus resources towards the advancement of our gene therapy pipeline and also concluding collaborations which validate our platform such as a hemophilia B partnership.  We ultimately believe that this transaction offers the renewed possibility of a meaningful exit for our shareholders, allowing them to benefit from the potential future upside in the business, including the possible outcome of the reconsideration by CHMP of our Glybera product.”

 

On the basis that the Transaction is in the best interests of AMT, its stakeholders, and the business, the Special Committee supports the Transaction and shall recommend the Extraordinary General Meeting of shareholders (“EGM”) to be held on March 30, 2012 to approve the Transaction.

 

uniQure will continue with AMT’s strategy to invest in the hemophilia B, GDNF and AIP programs, as well as the collaboration with Institut Pasteur on Sanfilippo B, but will not invest significant additional funds into Glybera unless and until it receives a positive decision from regulatory authorities.  All employees of AMT will continue in employment with uniQure on the same terms.  The members of the Supervisory and Management Boards will also transfer to uniQure, with the exception of Mr. Ferdinand Verdonck, who chairs the Special Committee.  Further terms of the Agreement and information on uniQure are set out below in a circular to Shareholders (“Shareholder Circular”), copies of which can be obtained free of charge from the Company’s office and at the Company’s website (www.amtbiopharma.com).

 

 

New funding, conversion of convertible loan notes and further information on uniQure

 

UniQure has been specifically created for the Transaction and financing, and has no other assets or liabilities.

 

Upon completion, Forbion Capital managed funds will subscribe € 6.0 million in new equity for 9.771.987 ordinary shares in uniQure at an issue price of €0.614 per share, being the mean closing share price of AMT on NYSE Euronext in Amsterdam for the five business days prior to the date the Business Acquisition Agreement was entered into.  This additional financing from Forbion funds is conditional on AMT securing an additional € 1.0 million in new equity funding on the same terms from other sources.  Together, the € 7.0 million in new financing will secure the immediate future of the AMT business and is expected to enable the successful conclusion of the current partnering negotiations relating to the hemophilia B program.  The majority of this new Forbion funding comes from funds that are only permitted to invest in unlisted companies and this money is therefore not available to AMT directly.

 

Following completion, the transferred liabilities relating to the convertible loan notes shall be converted to 5,320,000 ordinary shares in uniQure using a conversion price of € 1.00 per share.  Following the Transaction Forbion will be the largest shareholder in uniQure with significant rights relating to the conduct and governance of the business.

 

Each AMT shareholder that on the Distribution Record Date holds at least 1.555.054 shares in AMT and that will hence receive at least 1.555.054 DRs shall be entitled to exchange its DRs for an equal number of ordinary shares in uniQure.  Each AMT shareholder with fewer AMT shares shall receive the equivalent number of DRs but shall not be entitled to exchange its DRs for an equal number of ordinary shares in uniQure.

 

uniQure will be subject to certain terms and conditions relating to its governance and operation; these are described further in the Shareholder Circular.

 

 

Extraordinary General Meeting

 

An EGM has been convened for March 30, 2012 to approve the Transaction and resolve on certain related matters, as set out in the agenda and the explanatory notes thereto, which are available through the company’s website.

 

Forbion has committed to vote in favour of the Transaction in respect of the 19.4% of AMT’s shares it controls.

 

Shareholder information meetings

 

AMT will hold two information meetings for shareholders at its offices on February 23, 2012 and March [20], 2012.  Further details will be posted on the AMT website.

 

About Amsterdam Molecular Therapeutics

 

AMT is a world leader in the developing of human gene based therapies.  AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson’s disease and Sanfilippo.  Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world’s first stable and scalable AAV manufacturing platform.  This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam.  Further information can be found at www.amtbiopharama.com.

 

About uniQure

 

uniQure BV is a private company created specifically for the Transaction.  It is funded by Forbion Capital Partners, an existing investor in AMT.  uniQure will act as the new holding company for the gene therapy business currently carried out by AMT.

 

	
For   further enquiries:
    	
 
    	
 
    
	
Jörn   Aldag
    	
Mike   Sinclair
    	
Sander   Slootweg
    
	
CEO
    	
Partner
    	
General   Partner
    
	
AMT
    	
Halsin   Partners
    	
Forbion   Capital
    
	
Partners
    	
 
    	
 
    

 

 

	
Tel:   +31 20 566 8014
    	
Tel:   +44 20 7318 2955
    	
Tel:   +44 20 7457 2029
    
	
j.aldag@amtbiopharma.com
    	
msinclair@halsin.com
    	
 
    
	
 
    	
forbion@collegehill.com
    	
 
    

 

Certain statements in this press release are “forward-looking statements” including those that refer to management’s plans and expectations for future operations, prospects, and financial condition.  Words such as “strategy,” “expects,” “plans,” “anticipates,” “believes,” “will,” “continues,” “estimates,” “intends,” “projects,” “goals,” “targets,” and other words of similar meaning are intended to identify such forward-looking statements.  Such statements are based on the current expectations of the management of AMT only.  Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT.  Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT’s business.  AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.

 

Not for release, publication or distribution in whole or in part, directly or indirectly, in or into the United States or to US persons.  This announcement is not a prospectus and does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States or any other jurisdiction.

 

The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, taken up, exercised, renounced, transferred or delivered, directly, or indirectly, within the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.  No public offering of the securities mentioned herein is being made in the United States or any other jurisdiction.

 

This announcement does not constitute or forms a part of any offer to solicitation to purchase or subscribe for securities in any jurisdiction or jurisdictions in which such

 

 

offers or sales are unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

The materials contained herein have not been submitted to or reviewed by the US Securities and Exchange Commission (the “SEC”) or any state securities commission, and neither the SEC nor any such state securities commission has (a) approved or disapproved, (b) passed upon the merits of fairness of, or (c) passed upon the adequacy or accuracy of the disclosure of any materials contained herein.  Any representation to the contrary is a criminal offence in the United States.

 

 

SCHEDULE 8— NOTICES

 

All announcements or notices to the Seller shall be sent to the following address or to the following fax number:

 

	
Name
    	
:
    	
Amsterdam Molecular Therapeutics (AMT) N.V.
    
	
Attn
    	
:
    	
Mr. Joern Aldag
    
	
Address
    	
:
    	
Meibergdreef 61, 1105 BA
    
	
Place of residence
    	
:
    	
Amsterdam
    
	
Country
    	
:
    	
The Netherlands
    
	
Email
    	
:
    	
j.aldag@amtbiopharma.com
    

 

With a copy to:

 

	
Name
    	
:
    	
Simmons & Simmons LLP
    
	
Attn
    	
:
    	
Mr. Michiel Wurfbain
    
	
Address
    	
:
    	
Claude Debussylaan 247, 1082 MC
    
	
Place of residence
    	
:
    	
Amsterdam
    
	
Country
    	
:
    	
The Netherlands
    
	
Email
    	
:
    	
michiel.wurfbain@simmons-simmons.com
    

 

as long as the Seller does not give notice to the other Parties of any other address.

 

All announcements or notices to the Purchaser shall be sent to the following address or to the following fax number:

 

	
Name
    	
:
    	
uniQure B.V.
    
	
Attn
    	
:
    	
Vincent van Houten
    
	
Address
    	
:
    	
Gooimeer 2 35, 1411 DC
    
	
Place of residence
    	
:
    	
Naarden
    
	
Country
    	
:
    	
The Netherlands
    
	
Email
    	
:
    	
Vincent.van.Houten@forbion.com
    

 

With a copy to:

 

	
Name
    	
:
    	
Stibbe
    
	
Attn
    	
:
    	
Mr. Egbert Vroom
    
	
Address
    	
:
    	
Strawinskylaan 2001, 1077 ZZ
    
	
Place of residence
    	
:
    	
Amsterdam
    
	
Country
    	
:
    	
The Netherlands
    
	
Email
    	
:
    	
Egbert.vroom@stibbe.com
    

 

as long as the Seller does not give notice to the other Parties of any other address.

 

5

 

All announcements or notices to AMT BV and/or AMT IP BV shall be sent to the following address or to the following fax number:

 

	
Name
    	
:
    	
Amsterdam Molecular Therapeutics (AMT) B.V. or Amsterdam Molecular   Therapeutics (AMT)IP B.V.
    
	
Attn
    	
:
    	
Mr. Joern Aldag
    
	
Address
    	
:
    	
Meibergdreef 61, 1105 BA
    
	
Place of residence
    	
:
    	
Amsterdam
    
	
Country
    	
:
    	
The Netherlands
    
	
Email
    	
:
    	
j.aldag@amtbiopharma.com
    

 

With a copy to:

 

	
Name
    	
:
    	
Simmons & Simmons LLP
    
	
Attn
    	
:
    	
Mr. Michiel Wurfbain
    
	
Address
    	
:
    	
Claude Debussylaan 247, 1082 MC
    
	
Place of residence
    	
:
    	
Amsterdam
    
	
Country
    	
:
    	
The Netherlands
    
	
Email
    	
:
    	
michiel.wurfbain@simmons-simmons.com
    

 

as long as AMT BV and/or AMT IP BV does not give notice to the other Parties of any other address.

 

All announcements or notices to the Investor shall be sent to the following address or to the following fax number:

 

	
Name
    	
:
    	
Forbion Capital Partners
    
	
Attn
    	
:
    	
Vincent van Houten
    
	
Address
    	
:
    	
Gooimeer 2 35, 1411 DC
    
	
Place of residence
    	
:
    	
Naarden
    
	
Country
    	
:
    	
The Netherlands
    
	
Email
    	
:
    	
Vincent.van.Houten@forbion.com
    

 

With a copy to:

 

	
Name
    	
:
    	
Stibbe 
    
	
Attn
    	
:
    	
Mr. Egbert Vroom
    
	
Address
    	
:
    	
Strawinskylaan 2001, 1077 ZZ
    
	
Place of residence
    	
:
    	
Amsterdam
    
	
Country
    	
:
    	
The Netherlands
    
	
Email
    	
:
    	
Egbert.vroom@stibbe.com
    

 

as long as the Investor does not give notice to the other Parties of any other address.

 

6Exhibit 10.30

 

DATED 5 APRIL 2012

 

Amsterdam Molecular Therapeutics (AMT) B.V.

 

and

 

Amsterdam Molecular Therapeutics (AMT) IP B.V.

 

as the Transferees

 

and

 

Amsterdam Molecular Therapeutics (AMT) Holding N.V.

 

as the Transferor

 

 

DEED OF ASSIGNMENT OF
 CERTAIN ASSETS AND
 LIABILITIES OF AMSTERDAM
 MOLECULAR THERAPEUTICS
 (AMT) HOLDING N.V.

 

 

 

 

TABLE OF CONTENTS

 

	
Clause
    	
 
    	
Headings
    	
 
    	
Page
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
1.
    	
 
    	
INTERPRETATION
    	
 
    	
2
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
2.
    	
 
    	
TRANSFER OF OWNERSHIP
    	
 
    	
2
    
	
 
    	
 
    	
2.1.
    	
Agreement to transfer
    	
 
    	
2
    
	
 
    	
 
    	
2.2.
    	
Business Goodwill and Know How
    	
 
    	
2
    
	
 
    	
 
    	
2.3.
    	
Business Intellectual Property Rights
    	
 
    	
2
    
	
 
    	
 
    	
2.4.
    	
Business Assets
    	
 
    	
3
    
	
 
    	
 
    	
2.5.
    	
Business Liabilities
    	
 
    	
3
    
	
 
    	
 
    	
2.6.
    	
Contracts and Business Permits
    	
 
    	
3
    
	
 
    	
 
    	
2.7.
    	
Other assets and liabilities
    	
 
    	
3
    
	
 
    	
 
    	
2.8.
    	
Excluded assets and liabilities
    	
 
    	
3
    
	
 
    	
 
    	
2.9.
    	
Other transfer requirements
    	
 
    	
4
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
3.
    	
 
    	
TRANSFER OF SELLER LOANS
    	
 
    	
4
    
	
 
    	
 
    	
3.1.
    	
Agreement to transfer
    	
 
    	
4
    
	
 
    	
 
    	
3.2.
    	
VAT
    	
 
    	
4
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
4.
    	
 
    	
ECONOMIC OWNERSHIP TRANSFER AGREEMENT
    	
 
    	
5
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
5.
    	
 
    	
GOVERNING LAW AND JURISDICTION
    	
 
    	
5
    
	
 
    	
 
    	
5.1.
    	
Governing law
    	
 
    	
5
    
	
 
    	
 
    	
5.2.
    	
Jurisdiction
    	
 
    	
5
    

 

 

THIS DEED is made on 5 April 2012.

 

BETWEEN:

 

(1)                                Amsterdam Molecular Therapeutics (AMT) B.V., a company incorporated under the laws of the Netherlands with its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce with number 34275365;

 

(2)                                Amsterdam Molecular Therapeutics (AMT) IP B.V., a company incorporated under the laws of the Netherlands with its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce with number 34275369;

 

(Amsterdam Molecular Therapeutics (AMT) B.V. and Amsterdam Molecular Therapeutics (AMT) IP B.V. collectively also the “Transferees” and each individually a “Transferee”), and

 

(3)                                Amsterdam Molecular Therapeutics (AMT) Holding N.V., a company incorporated under the laws of the Netherlands with its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce with number 33301321 (the “Transferor”)

 

The parties to this Agreement are hereinafter collectively referred to as the “Parties” and individually as a “Party”.

 

RECITALS:

 

(1)                                Pursuant to an agreement dated 16 February 2012 (the “Economic Ownership Transfer Agreement”) the Transferor contributed the economic ownership (economische eigendom) of the Business (as defined in the Economic Ownership Transfer Agreement) to the Transferees subject to and upon the terms and conditions of the Economic Ownership Transfer Agreement.

 

(2)                                The Transferor and the Transferees wish to transfer the legal title (juridische eigendom) to the Business to the Transferees as contemplated in the Economic Ownership Transfer Agreement by entering into this asset transfer agreement (the “Deed of Assignment”) and performing all other actions necessary to transfer the legal title to, and therefore the ownership of, the Business to the Transferees in accordance with Clause 2 of the Economic Ownership Transfer Agreement.

 

(3)                                The conditions stipulated in Clause 3 of the Economic Ownership Transfer Agreement have been fulfilled or waived and parties have agreed that the legal titel of the Business shall be transferred on the execution of this Deed of Assignment, but prior to the Completion Date.

 

(4)                                Furthermore, the Transferor and the Transferees wish to transfer the legal title (juridische eigendom) and the economic ownership (economische eigendom) of the Seller Loans to the Transferees and to effectuate such transfer by entering into this Deed of Assignment and performing all other actions necessary to effectuate such transfer.

 

(5)                                The Transferor has obtained all internal corporate approvals required for the execution and performance of this Deed of Assignment.

 

1

 

IT IS AGREED as follows:

 

1.                                     INTERPRETATION

 

Definitions used in this Deed of Assignment have the same meaning as given to them in the Economic Ownership Transfer Agreement unless stated otherwise, and the provisions of Clause 1 (Interpretation) of the Economic Ownership Transfer Agreement shall apply to this Agreement.

 

2.                                     TRANSFER OF OWNERSHIP

 

2.1.                           Agreement to transfer

 

2.1.1.                           Subject to the terms and conditions of this Deed of Assignment and the Economic Ownership Transfer Agreement, the Transferor hereby transfers and delivers the legal title to the Business to the Transferees and the Transferees hereby accept and assume from the Transferor the Business, including the Business Assets and the Business Liabilities, whereby:

 

(A)                              the legal title to the Business Intellectual Property Rights is transferred to AMT IP BV; and

 

(B)                              the legal title to the other Business Assets and Business Liabilities is transferred to AMT BV.

 

2.1.2.                           The Transferees and the Transferor acknowledge that to the extent the transfer and delivery of any of the Business Assets and/or Business Liabilities requires a deed (akte) this Deed of Assignment constitutes a deed of transfer for such Business Assets and Business Liabilities to take effect from the execution of this Deed of Assignment.

 

2.1.3.                           The transfer and delivery of the Business Assets and Business Liabilities shall further be effectuated as set out in Clause 2 of the Economic Ownership Transfer Agreement.

 

2.1.4.                           The legal title to the respective parts of the Business shall be transferred to AMT IP BV and AMT BV by way of a contribution in kind (inbreng in natura) on the ordinary shares in the capital of the Transferees held by the Transferor, without the issuance of new shares. The value of such contribution will be recorded as share premium (agiostorting) in the books of AMT IP BV and AMT BV.

 

2.2.                           Business Goodwill and Know How

 

The Business Goodwill and Know How are hereby transferred to the Transferees.

 

2.3.                           Business Intellectual Property Rights

 

The Business Intellectual Property Rights are hereby transferred to AMT IP BV. AMT IP BV shall register the registered Business Intellectual Property Rights in its name in all relevant registers. To the extent any of the Business Intellectual Property Rights consists of a license (“Business Permit”), such license shall, if permitted under the license, be transferred in accordance with the relevant requirements of such license and in accordance with Clause 2.6, simultaneously with the execution of this Deed of Assignment.

 

2

 

2.4.                           Business Assets

 

2.4.1.                           All Business Assets, including but not limited to ICT, inventory and equipment, business records, business stock and work in progress and all other Business Assets that are transferable by delivery (bezitsverschaffing), to the extent such Business Assets are not held by others for or on behalf of the Transferor, are hereby transferred and delivered to the relevant Transferee by giving access to the places where these Business Assets are physically located and by having delivered to the relevant Transferee all keys and title documents and other evidence of ownership.

 

2.4.2.                           To the extent that any of the Business Assets that are mentioned in Clause 2.4.1 are held by others for or on behalf of the Transferor, such Business Assets are transferred and delivered to the relevant Transferee by a notice from the Transferor to the other parties, also on behalf of the relevant Transferee, instructing such party to hold such Business Assets for or on behalf of the relevant Transferee to take effect prior to the Completion Date. The Transferor shall send the relevant Transferee a copy of such notices.

 

2.4.3.                           To the extent any of the Business Assets consists of a license, such license shall, if permitted under the license, be transferred in accordance with the relevant requirements of such license and in accordance with Clause 2.6 simultaneously with the execution of this Deed of Assignment.

 

2.5.                           Business Liabilities

 

The Business Liabilities are hereby transferred to the relevant Transferee in accordance with the terms and conditions of the Economic Ownership Transfer Agreement.

 

2.6.                           Contracts and Business Permits

 

All Contracts and Business Permits are hereby transferred to the relevant Transferee in accordance with the relevant requirements of such Contract or Business Permit and the terms and conditions of the Economic Ownership Transfer Agreement.

 

2.7.                           Other assets and liabilities

 

Notwithstanding the provisions of Clause 2.1 up to and including 2.6, the Transferor hereby transfers and delivers the legal title of all other existing assets, business assets, liabilities and/or contracts of the Transferor, if any, to AMT BV and AMT BV hereby acquire and accept from the Transferor all such other assets, including but not limited to cash, business assets, liabilities and/or contracts.

 

2.8.                           Excluded assets and liabilities

 

The provisions of this Deed of Assignment do not extend to the Loan Notes, Convertible Loan Note Agreement, Sale Shares, Administration, rights and obligations pursuant to the BAA, the listing agreement between the Transferor and Euronext Amsterdam, the contract with the ENL agent and the payment agent, the liquidity provider agreement between the Transferor and Kempen & Co N.V., the D&O Insurance policy of the Transferor, any outstanding obligations under any stock option plan or other employee plan of the Transferor and any and all agreements the Transferor entered into with Senter Novem. This

 

3

 

Deed of Assignment does therefore not constitute a transfer of the legal title to any of the assets and contracts mentioned in this Clause 2.8.

 

2.9.                           Other transfer requirements

 

If and insofar the transfer of any existing Business Assets or Business Liabilities requires any other acts for the transfer of the legal title to such Business Assets or Business Liabilities than mentioned in this Deed of Assignment, Parties shall satisfy such requirements and comply with the relevant statutory provisions, as soon as reasonably and practically possible.

 

3.                                     TRANSFER OF SELLER LOANS

 

3.1.                           Agreement to transfer

 

3.1.1.                           Subject to the terms and conditions of this Deed of Assignment the Transferor hereby contributes to

 

(A)                              AMT BV and AMT BV hereby accept from the Transferor, the legal title and economic ownership of the AMT BV Seller Loan; and

 

(B)                              AMT IP BV and AMT IP BV hereby accept from the Transferor, the legal title and economic ownership of the AMT IP BV Seller Loan.

 

3.1.2.                           The AMT BV Seller Loan and the AMT IP BV Seller Loan are with the effect as of the signing date of this Deed of Assignment transferred to AMT BV and AMT IP BV, respectively, by way of a contribution in kind (inbreng in natura) on the ordinary shares in the capital of AMT BV and AMT IP BV held by the Transferor, without the issuance of new shares. The value of the AMT BV Seller Loan and the AMT IP BV Seller Loan will be recorded as share premium (agiostorting) in the books of AMT BV and AMT IP BV.

 

3.1.3.                           As a result of the contribution set forth in Clause 3.1 above:

 

(A)                              AMT BV is both the debtor and the creditor under the AMT BV Seller Loan; and

 

(B)                              AMT IP BV is both the debtor and the creditor under the AMT IP BV Seller Loan,

 

resulting in the cancellation of the AMT BV Seller Loan and the AMT IP BV Seller Loan.

 

3.2.                           VAT

 

The Transferor and the Transferees are included in a fiscal unity for Dutch VAT purposes within the meaning of article 7 paragraph 4 Dutch VAT Act 1968 (Wet op de omzetbelasting 1968) and the Transferor and the Transferees expressly agree that the transfer of the legal title and economic ownership of the Seller Loans occurs within the fiscal unity for Dutch VAT and that therefore no VAT should become due as a result of such transfer.

 

4

 

4.                                     ECONOMIC OWNERSHIP TRANSFER AGREEMENT

 

The Economic Ownership Transfer Agreement constitutes an integral part of this Deed of Assignment and is hereby incorporated into this Deed of Assignment by this reference. This Deed of Assignment shall in no way impair or affect the Economic Ownership Transfer Agreement that shall remain in full force and effect despite Completion.

 

5.                                     GOVERNING LAW AND JURISDICTION

 

5.1.                           Governing law

 

This Deed of Assignment is governed by the laws of the Netherlands, but excluding the Vienna Convention for the International Sale of Goods.

 

5.2.                           Jurisdiction

 

The competent court in Amsterdam, the Netherlands, shall have exclusive jurisdiction to settle any dispute in connection with this Deed of Assignment without prejudice to the right of appeal and that of appeal to the Supreme Court.

 

5

 

THUS AGREED AND SIGNED ON 5 APRIL 2012,

 

 

	
Amsterdam   Molecular Therapeutics (AMT) B.V.
    	
 
    	
Amsterdam   Molecular Therapeutics (AMT) IP B.V.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By: /s/Joern   Aldag
    	
 
    	
By: /s/Joern   Aldag
    
	
 
    	
 
    	
 
    
	
Title: CEO
    	
 
    	
Title: CEO
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Amsterdam   Molecular Therapeutics (AMT) Holding N.V.
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By: /s/Joern   Aldag
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Title: CEO
    	
 
    	
 
    

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]